**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 52439

**Manuscript Type:** REVIEW

**Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions**

Czaja AJ*.* Pathogenic concepts of autoimmune hepatitis

Albert J Czaja

**Albert J Czaja,** Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, United States

**ORCID number:** Albert J Czaja (0000-0002-5024-3065).

**Author contributions:** Czaja AJ researched, designed, and wrote this article; The 4 tables and 2 color figures are original, constructed by Czaja AJ, and developed solely for this review; The review article is original, current, and comprehensive, and it has not been published previously.

**Conflict-of-interest statement:** Albert J Czaja has no conflict of interests to declare.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited Manuscript

**Corresponding author: Albert J Czaja, FAASLD, AGAF, FACG, FACP, MD, Professor Emeritus of Medicine,** Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science,200 First Street S.W.,Rochester, MN 55905, United States. [czaja.albert@mayo.edu](mailto:czaja.albert@mayo.edu)

**Telephone:** +1-507-2842691

**Fax:** +1-507-2840538

**Received:** November 1, 2019

**Peer-review started:** November 1, 2019

**First decision:** November 22, 2019

**Revised:** November 25, 2019

**Accepted:** November 29, 2019

**Article in press:**

**Published online:**

**Abstract**

Multiple pathogenic mechanisms have been implicated in autoimmune hepatitis, but they have not fully explained susceptibility, triggering events, and maintenance or escalation of the disease. Furthermore, they have not identified a critical defect that can be targeted. The goals of this review are to examine the diverse pathogenic mechanisms that have been considered in autoimmune hepatitis, indicate investigational opportunities to validate their contribution, and suggest interventions that might evolve to modify their impact. English abstracts were identified in PubMed by multiple search terms. Full length articles were selected for review, and secondary and tertiary bibliographies were developed. Genetic and epigenetic factors can affect susceptibility by influencing the expression of immune regulatory genes. Thymic dysfunction, possibly related to deficient production of programmed cell death protein-1, can allow autoreactive T cells to escape deletion, and alterations in the intestinal microbiome may help overcome immune tolerance and affect gender bias. Environmental factors may trigger the disease or induce epigenetic changes in gene function. Molecular mimicry, epitope spread, bystander activation, neo-antigen production, lymphocytic polyspecificity, and disturbances in immune inhibitory mechanisms may maintain or escalate the disease. Interventions that modify epigenetic effects on gene expression, alter intestinal dysbiosis, eliminate deleterious environmental factors, and target critical pathogenic mechanisms are therapeutic possibilities that might reduce risk, individualize management, and improve outcome. In conclusion, diverse pathogenic mechanisms have been implicated in autoimmune hepatitis, and they may identify a critical factor or sequence that can be validated and used to direct future management and preventive strategies.

**Key words:** Autoimmune hepatitis; Pathogenesis; Epigenetics; Molecular mimicry; Epitope spread; Intestinal microbiome

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The next generation of management of autoimmune hepatitis will depend on clarification of the pathogenic sequence from susceptibility to triggering events to disease maintenance or escalation. Studies that move the pathogenesis of autoimmune hepatitis closer to its cause have the potential to replace blanket immunosuppressive regimens and even suggest strategies for prevention. Investigations that expand concepts of acquired epigenetic change in gene expression, pathogenic molecular mimicries, epitope spread, bystander activation, and intestinal dysbiosis may narrow the knowledge gap between environmental factors and disease occurrence and behavior. Protective as well as site-specific corrective interventions may emerge.

Czaja AJ. Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions. *World J Gastroenterol* 2019; In press

**INTRODUCTION**

Autoimmune hepatitis is an immune-mediated chronic liver disease that lacks a demonstrable etiologic agent[[1](#_ENREF_1)]. The diagnosis requires histological features of interface hepatitis, increased serum immunoglobulin G level, the presence of autoantibodies, and the exclusion of virus-related, drug-induced, metabolic, and hereditary diseases[[1](#_ENREF_1),[2](#_ENREF_2)]. Type 1 autoimmune hepatitis is characterized by the presence of antinuclear antibodies and/or smooth muscle antibodies, and type 2 autoimmune hepatitis is characterized by the presence of antibodies to liver kidney microsome type 1 (anti-LKM1)[[3](#_ENREF_3),[4](#_ENREF_4)]. Other autoantibodies that may be useful in the diagnosis of type 1 disease are antibodies to actin (anti-actin)[[5-8](#_ENREF_5)], antibodies to soluble liver antigen[[9](#_ENREF_9),[10](#_ENREF_10)], and atypical perinuclear anti-neutrophil cytoplasm antibodies[[11](#_ENREF_11),[12](#_ENREF_12)]. Antibodies to liver cytosol type 1 may be useful in the diagnosis of type 2 disease[[13-15](#_ENREF_13)].

Pathogenic concepts have indicated a genetic susceptibility for autoimmune hepatitis[[16-18](#_ENREF_16)], and deficiencies or disruptions in homeostatic mechanisms have been described that can overcome self-tolerance[[19-22](#_ENREF_19)]. These elements have not been formulated into a validated sequence that fully explains susceptibility, disease onset, and course. Furthermore, a critical pathogenic defect has not been identified that can be selectively targeted by a designed intervention.

A pathogenic hypothesis that can accommodate the clinical experiences and science of autoimmune hepatitis cannot exclude genetic makeup as a predisposing factor, but it must also integrate other factors to help explain the risk burden[[19](#_ENREF_19),[23](#_ENREF_23),[24](#_ENREF_24)]. Epigenetic changes could translate environmental cues into alterations of gene expression that disrupt pathways modulating the immune response[[25](#_ENREF_25),[26](#_ENREF_26)], and thymic failure may allow autoreactive T cells to escape negative selection[[27-29](#_ENREF_27)] and help explain susceptibility to the disease.

Molecular mimicry could be a mechanism for foreign antigens (infectious agents, drugs, xenobiotic chemicals, and gut-derived bacteria) to overcome self-tolerance[[30-33](#_ENREF_30)]. Bystander activation could release pro-inflammatory cytokines, generate autoreactive T cells, and intensify the immune response[[34-36](#_ENREF_34)]. Epitope spread could extend immune reactivity to less dominant epitopes within the same or other molecules[[37-41](#_ENREF_37)]; neo-antigens generated by tissue injury could expand the number of antigenic targets[[34](#_ENREF_34),[42](#_ENREF_42)]; and polyspecificity of the T cell antigen receptors (TCRs) could facilitate cross-reactivity between foreign and self-antigens[[43-45](#_ENREF_43)]. These mechanisms could help explain how environmental triggers can overcome immune tolerance and induce the disease. Furthermore, variations in the composition of the intestinal microbiome could allow microbial antigens and gut-driven immune cells to individualize the risk, clinical phenotype, and consequences of autoimmune hepatitis[[46](#_ENREF_46)].

The goals of this review are to examine the diverse mechanisms that have been implicated in the susceptibility, onset, and maintenance of autoimmune hepatitis, indicate investigational opportunities to validate their pathogenic roles, and suggest future interventions that might modify their impact.

**METHODS**

English abstracts were identified in PubMed using the primary search words, “pathogenesis of autoimmune hepatitis”, “genetics of autoimmune hepatitis”, “epigenetics and autoimmunity”, “pathogens and autoimmune hepatitis”, “drug-induced autoimmune hepatitis”, “molecular mimicry and autoimmune disease,” “neo-antigens”, “bystander activation”, “epitope spread”, “intestinal microbiome and autoimmune disease”, and “environment and autoimmunity”. Abstracts judged pertinent to the review were identified; key aspects were recorded; and full-length articles were selected from relevant abstracts. A secondary bibliography was developed from the references cited in the selected full-length articles, and additional PubMed searches were performed to expand the concepts developed in these articles. The discovery process was repeated, and a tertiary bibliography was developed after reviewing selected articles from the secondary bibliography. Over 1500 abstracts and 100 full length articles were reviewed.

**FACTORS AFFECTING SUSCEPTIBILITY**

***Genetic predisposition***

Genetic associations inside and outside the major histocompatibility complex (MHC) have been associated with the occurrence, serological phenotype, and severity of autoimmune hepatitis[[18](#_ENREF_18),[47](#_ENREF_47),[48](#_ENREF_48)], and these associations have varied between ethnic groups[[16](#_ENREF_16),[49-51](#_ENREF_49)], geographical regions[[52-56](#_ENREF_52)], and age ranges[[57](#_ENREF_57),[58](#_ENREF_58)] (Table 1). Genetic factors within the MHC may predispose to autoimmune hepatitis by encoding antigen binding grooves on class II MHC molecules that select and present antigens with certain structural and conformational properties[[17](#_ENREF_17),[59](#_ENREF_59)], and genetic factors outside the MHC (polymorphisms of key immune regulatory and cytokine-producing genes) may promote immune reactivity and inflammatory responses that affect clinical phenotype and disease severity[[48](#_ENREF_48),[60-62](#_ENREF_60)] (Figure 1).

The triggering peptides may be common in particular sub-populations, such as the young (viral infections) or the elderly (polypharmacy), and they may reflect the genetic composition and environment of the population at risk. HLA DRB1\*03 has a low frequency in the normal Japanese population, and autoimmune hepatitis in Japan is associated mainly with HLA DRB1\*04[[49](#_ENREF_49)]. In contrast, HLA DRB1\*04 is less frequent in the normal Italian population than in healthy North American adults (16% *vs* 34%, *P* = 0.0003)[[63](#_ENREF_63)]. These differences in the genetic composition of the populations at risk could affect antigen selection, disease occurrence, and clinical phenotype.

Future studies of genetic and environmental factors associated with autoimmune hepatitis should be population-based and correlate genetic determinants with age, gender, ethnicity, and exposure to possible antigenic triggers[[64](#_ENREF_64)]. Importantly, the risk-burden for autoimmune hepatitis cannot be fully explained by genetic factors[[23](#_ENREF_23)]. The key susceptibility alleles (*DRB1\*03:01* and *DRB1\*04:01*) occur in only 51%-55% of white North American and northern European patients[[16](#_ENREF_16)], and polymorphisms of genes outside the MHC, which have yet to be ascribed biological significance, have similar frequencies of occurrence[[23](#_ENREF_23),[25](#_ENREF_25),[60](#_ENREF_60),[65](#_ENREF_65),[66](#_ENREF_66)]. Population-based genome-wide association studies may define the genetic fabric outside the MHC that is still undiscovered in autoimmune hepatitis, and epigenetic changes, cued by the environment, may also explain the risk.

***Epigenetic changes***

Epigenetic changes influence the function of genes without altering the sequence of deoxyribonucleic acid (DNA), and they may contribute to the occurrence and phenotype of autoimmune hepatitis[[25](#_ENREF_25),[26](#_ENREF_26)] (Table 1). They may also explain the risk-burden for autoimmune hepatitis that cannot be linked to classical genetic associations. Epigenetic changes can occur at sites throughout the genome and respond to pressures that reflect diverse environmental factors[[26](#_ENREF_26),[67](#_ENREF_67)] (Figure 1). The structural adaptations occur within the nucleosomes of chromatin, and they affect the packaging of DNA, the activity of ribonucleic acid polymerase (RNAP), the ability of RNAP to open double-stranded DNA, and the accessibility of transcription factors to DNA binding sites[[67-69](#_ENREF_67)]. DNA methylation[[70](#_ENREF_70)] and histone modification[[71](#_ENREF_71),[72](#_ENREF_72)] are the principal mechanisms that modify chromatin structure, and noncoding micro-ribonucleic acids (miRNAs)[[73-76](#_ENREF_73)] are the main agents that silence gene activity.

***DNA methylation, histone modifications, and miRNAs***

DNA methylation typically represses gene activity by inhibiting the binding of transcription factors to DNA, and it can be reversed by oxidation of the methylated site[[26](#_ENREF_26),[77](#_ENREF_77),[78](#_ENREF_78)] (Table 1). The ten eleven translocation oxygenases catalyze this conversion, increase gene translational activity, and counterbalance the repressive effects of DNA methylation[[79-81](#_ENREF_79)]. Hypomethylation of gene promoters has been described in systemic lupus erythematosus (SLE)[[82](#_ENREF_82),[83](#_ENREF_83)] and primary biliary cholangitis (PBC)[[84](#_ENREF_84)], and epigenetic alterations in the expression of immune regulatory genes may promote loss of self-tolerance[[85](#_ENREF_85)].

Histone modifications involve enzymatic alterations of amino acids in the tail of the histone proteins comprising the nucleosomes, and these modifications (phosphorylation, methylation, acetylation, and ubiquitination) can in turn loosen the wrap of DNA and increase the transcriptional activity of the gene[[25](#_ENREF_25),[72](#_ENREF_72),[86](#_ENREF_86),[87](#_ENREF_87)] (Table 1). Histone acetylation by histone acetyltransferase characterizes activated genes which may have stimulatory or repressive effects on disease activity by increasing the number and function of regulatory T cells (Tregs)[[88](#_ENREF_88)] or increasing the expression of pro-inflammatory genes[[89](#_ENREF_89)]. Histone deacetylase can modulate transcription activity by removing acetyl groups and repressing gene activity[[90-92](#_ENREF_90)]. The number and location of possible histone modifications within the nucleosome contribute to genomic instability, and histone modifications have been associated with the loss of self-tolerance[[71](#_ENREF_71),[92](#_ENREF_92),[93](#_ENREF_93)].

Noncoding miRNAs are small double-stranded molecules that can pair with similarly sequenced messenger RNAs (mRNAs) within the cytosol. The complex is destined for degradation by a RNA-induced silencing complex[[73](#_ENREF_73),[94-96](#_ENREF_94)] (Table 1). Gene silencing can have organ specificity, and it can occur by degradation or repression of the mRNAs[[97](#_ENREF_97)]. A single miRNA can affect the expression of multiple genes, and many different miRNAs can target the same mRNA. MiRNAs can thereby modulate disease activity by affecting immune (gene product production), inflammatory (cytokine production), and proliferative (lymphocyte differentiation) pathways[[98-100](#_ENREF_98)]. The investigational challenge is to identify within the body of described miRNAs (> 1400 types) the key gene products that are targeted in autoimmune hepatitis[[101](#_ENREF_101),[102](#_ENREF_102)].

***Epigenetic changes and autoimmune hepatitis***

Serum levels of micro-RNA 21 (miR-21) and micro-RNA 122 (miR-122) are increased in autoimmune hepatitis[[103](#_ENREF_103)] (Table 1). MiR-21 is expressed by T lymphocytes, and the programmed cell death4 (*PDCD4*) gene is one of its gene targets[[103](#_ENREF_103),[104](#_ENREF_104)]. The gene product of *PDCD4* is the immune inhibitory protein, PDCD-4, and the down-regulation of *PDCD4* by miR-21 could promote immune reactivity. PDCD-4 increases the apoptosis of activated T lymphocytes and decreases the production of pro-inflammatory cytokines[[105](#_ENREF_105)], and serum levels of miR-21 have correlated with the histological grade of liver inflammation[[103](#_ENREF_103)].

Similarly, miR-122 has been associated with inflammatory activity (serum alanine aminotransferase levels) in autoimmune hepatitis[[103](#_ENREF_103)], and miR-122 has increased the production of the pro-inflammatory cytokine, interferon type 1, by de-repressing cytokine signaling in a murine model of PBC[[105](#_ENREF_105)]. Both miR-21 and miR-122 have been proposed as biomarkers of inflammatory activity in autoimmune hepatitis, but the nature and scope of their actions, disease-specificity, and value as therapeutic targets remain uncertain[[103](#_ENREF_103)].

***Thymic failure and escaped autoreactive T cells***

Susceptibility to autoimmune disease may also relate to the escape of autoreactive immune cells from negative selection by the thymus and their persistence in the circulation (Figure 1). The existence of circulating autoreactive T cells implies a central defect in their thymic elimination or a peripheral failure to suppress their activity. Disruptions in the homeostatic molecular pathways that modulate negative selection within the thymus and lymphocyte differentiation in the lymphatic tissue have been proposed, and the expression of programmed cell death antigen-1 (PD-1) on thymocytes and maturing lymphocytes may be a key factor in limiting the escape and activity of autoreactive T cells[[22](#_ENREF_22)].

***Failures in thymic selection and peripheral protection***

Immature CD4-CD8- thymocytes differentiate into CD4+CD8+ thymocytes that are characterized by TCR beta (β)-chains (β-selection)[[106-109](#_ENREF_106)] (Table 1). The CD4+CD8+ thymocytes with β-chains develop TCRs consisting of alpha (α)- and β-chains, and only the thymocytes that survive selection by demonstrating TCR specificity can mature into CD4+ or CD8+ T lymphocytes (repertoire selection)[[110](#_ENREF_110),[111](#_ENREF_111)]. Thymocytes with self-reactive antigen receptors are eliminated by apoptosis (negative selection), and thymocytes that recognize foreign peptides presented by MHC molecules are selected to mature (positive selection)[[27-29](#_ENREF_27)].

Self-reactive CD4+ T cells that escape thymic deletion can autonomously express the immune inhibitory protein, PD-1, to induce self-tolerance[[112](#_ENREF_112)] (Table 1). Otherwise, the majority will persist as autoreactive T cells unless they express forkhead box P3 (FoxP3)[[112-114](#_ENREF_112)]. Self-reactive CD4+ T cells expressing FoxP3 can differentiate into Tregs and counteract the autoreactive response. This transformation into Tregs occurs in only a minority of the self-reactive T cells that have evaded thymic elimination, and its dampening effect on the autoreactive response may be incomplete or negligible[[112](#_ENREF_112),[113](#_ENREF_113),[115](#_ENREF_115)].

The expression of PD-1 on thymocytes[[109](#_ENREF_109),[116](#_ENREF_116)] and maturing lymphocytes[[112](#_ENREF_112)] is critical in limiting the emergence of autoreactive lymphocytes in the periphery. Clarification of the factors that regulate production and function of PD-1 should be an investigational objective in autoimmune hepatitis[[22](#_ENREF_22)]. Soluble PD-1 is an alternatively spliced transcript encoded by the PD-1 gene which lacks a membrane-spanning portion and is rendered soluble[[117](#_ENREF_117)]. The shortened soluble molecule is a variant of PD-1 that can competitively inhibit ligation of the full length molecule and prevent generation of an immune inhibitory signal[[117-119](#_ENREF_117)]. Its counter effects on the immune inhibitory actions of full-length PD-1 may contribute to the escape of autoreactive T cells, and soluble PD-1 should be evaluated as a potential biomarker of disease activity and therapeutic target in autoimmune hepatitis.

**TRIGGERING EVENTS**

***Microbial infection***

Clinical experiences have described temporal associations between viral infections and the onset of autoimmune hepatitis in isolated cases. Infections with hepatitis A virus[[120-125](#_ENREF_120)], hepatitis B virus (HBV)[[126](#_ENREF_126)], hepatitis C virus (HCV)[[127](#_ENREF_127)], Epstein-Barr virus (EBV)[[128-132](#_ENREF_128)], varicella zoster[[133](#_ENREF_133)], and human immunodeficiency virus[[134](#_ENREF_134)] have been proposed as triggering events (Table 2). Other studies have described evidence of HCV[[135-139](#_ENREF_135)], measles virus[[140-142](#_ENREF_140)], cytomegalovirus (CMV)[[143](#_ENREF_143)], and EBV[[144](#_ENREF_144)] in the serum or liver tissue of patients with autoimmune hepatitis. These findings have supported an association between viral infection and autoimmune hepatitis, but the nature of the relationship (coincidental *vs* etiologic) has been uncertain[[145](#_ENREF_145),[146](#_ENREF_146)].

The frequency of viral markers in patients with characteristic features of autoimmune hepatitis has been low (2%-11% for HCV and HBV)[[136](#_ENREF_136),[147](#_ENREF_147),[148](#_ENREF_148)], often associated with false positive first generation assays confounded by hypergammaglobulinemia[[149](#_ENREF_149),[150](#_ENREF_150)], and commonly unconfirmed by second generation assays[[147](#_ENREF_147)] (Table 2). The possibility of an undiscovered viral cause of autoimmune hepatitis cannot be excluded, but assessments for unusual viruses have been unrewarding (albeit few in number)[[151](#_ENREF_151),[152](#_ENREF_152)]. After decades of observation and pursuit, a particular viral trigger for autoimmune hepatitis has not been established. Instead, viruses may constitute one of several categories of environmental agents that expose individuals to antigens that pages challenge immune tolerance in susceptible individuals.

The ubiquity and diversity of the presumed viral agents and the rarity of autoimmune hepatitis suggest that infection must be accompanied by host specific factors to trigger autoimmunity[[147](#_ENREF_147)]. Genetic makeup[[17](#_ENREF_17),[153](#_ENREF_153)], dysregulated critical homeostatic pathways[[34](#_ENREF_34)], pre-conditioning by previous viral infections[[154](#_ENREF_154)], molecular mimicries between microbial and self-antigens[[30](#_ENREF_30),[31](#_ENREF_31),[155](#_ENREF_155),[156](#_ENREF_156)], and unmasked or newly created antigens (neo-antigens[[34](#_ENREF_34),[146](#_ENREF_146)] or superantigens[[157-159](#_ENREF_157)]) may constitute the host-specific factors that translate microbial infection into an autoimmune disease.

***Superantigens***

Viruses and bacteria can induce the formation of superantigens which can activate autoreactive T cells without antigen presentation by MHC molecules[[158](#_ENREF_158),[159](#_ENREF_159)] (Table 2). The superantigens are a family of proteins that can bind to class II molecules of the MHC on antigen presenting cells (APCs) at a site distant from the peptide binding groove[[158](#_ENREF_158)]. Simultaneously, they can bind to the TCR of T lymphocytes and activate them[[158](#_ENREF_158)]. Superantigens bind to the variable region of the β chain within the TCR[[160](#_ENREF_160)], and they frequently bind to several TCRs, thereby generating a polyclonal response[[161](#_ENREF_161)]. Virtually all T cells bearing a particular TCR Vβ are activated by a superantigen[[160](#_ENREF_160)], and the net effect is to trigger a T cell response manifested by the release of pro-inflammatory cytokines[[162](#_ENREF_162)] and the proliferation of T lymphocytes[[163](#_ENREF_163),[164](#_ENREF_164)].

Superantigens have been implicated as a reactivating factor in an experimental model of multiple sclerosis[[165](#_ENREF_165)] and a triggering factor in patients with rheumatoid arthritis[[166](#_ENREF_166),[167](#_ENREF_167)] (Table 2). The presence of a superantigen in patients with rheumatoid arthritis has been suspected because of the high percentage of Vβ14+ T cells in the synovial fluid and the oligoclonality of the Vβ14+ population[[166](#_ENREF_166)]. Similar studies assessing the Vβ repertoire of T cells in the liver tissue and peripheral blood in autoimmune hepatitis might also implicate a superantigen and extend the search for microbial triggers.

***Drug exposure***

Multiple drugs, especially minocycline, nitrofurantoin, and infliximab, can induce an idiosyncratic liver injury indistinguishable from autoimmune hepatitis[[168-170](#_ENREF_168)], and herbal medicines[[171-174](#_ENREF_171)] and environmental pollutants[[175](#_ENREF_175)] may also be initiating factors (Table 2). Drug-induced liver injury resembling autoimmune hepatitis is typically self-limited after drug withdrawal[[168](#_ENREF_168),[169](#_ENREF_169)], and the rare instances of chronic self-perpetuating liver injury may reflect host-specific deficiencies in immune regulation and antigens generated by interactions between reactive drug metabolites and self-proteins that promote loss of self-tolerance[[176-179](#_ENREF_176)].

The immune checkpoint inhibitors constitute an emerging category of biological agents that have been designed to block key immune inhibitory proteins [PD-1, programmed cell death antigen ligand-1, and cytotoxic T lymphocyte antigen-4 (CTLA-4)][[22](#_ENREF_22),[180](#_ENREF_180),[181](#_ENREF_181)] (Table 2). The immune checkpoint inhibitors have enhanced the adaptive immune response to neo-antigens expressed by tumor cells in animal models and patients[[182-185](#_ENREF_182)], and they have been associated with diverse immune-related adverse events[[186-189](#_ENREF_186)], including the development of an immune-mediated hepatitis[[190-194](#_ENREF_190)]. The clinical phenotype of liver injury induced by the immune checkpoint inhibitors has lacked the laboratory and histological features characteristic of autoimmune hepatitis[[191](#_ENREF_191),[195-198](#_ENREF_195)], but the delayed development of hepatitis 8 mo after discontinuation of an anti-PD-1 preparation suggests that induced disturbances in the immune inhibitory axis may endure and pose a long-term risk for immune-mediated liver disease[[189](#_ENREF_189)].

Drugs may also induce epigenetic changes that alter the expression of immune regulatory genes, and in turn this alteration that facilitate the loss of self-tolerance (Table 2). DNA demethylation has been associated with multiple drugs that can induce lupus-like reactions (procainamide, phenytoin, isoniazid, chlorpromazine, hydralazine, and 5-azacytidine)[[199-203](#_ENREF_199)], and demethylating drugs as initiating agents in autoimmune hepatitis have been under-evaluated[[25](#_ENREF_25),[169](#_ENREF_169)]. Aging may compound the effects of the environmental pressures on gene expression by promoting genomic instabilities through repeated cycles of DNA replication[[204-206](#_ENREF_204)].

Most cases of autoimmune hepatitis lack a definable etiological trigger, and the possibilities that an antecedent microbial infection or drug exposure has been overlooked or that multiple different microbial and drug exposures have had a cumulative deleterious effect on the maintenance of self-tolerance cannot be proven or denied[[146](#_ENREF_146)].

***Environmental pressures***

Epigenetic modifications can be induced by environmental pressures, and environmental cues that alter gene expression may help explain the occurrence of autoimmune hepatitis in diverse populations and geographical regions[[35](#_ENREF_35),[85](#_ENREF_85),[207](#_ENREF_207),[208](#_ENREF_208)] (Table 2). Vitamin D deficiency has been associated with histological severity, advanced hepatic fibrosis, and non-response to conventional glucocorticoid therapy in autoimmune hepatitis[[209-211](#_ENREF_209)]. 1, 25 dihydroxyvitamin D binds to the vitamin D receptor (VDR), and this complex in turn activates the vitamin D response element in certain genes. This epigenetic change may enhance the transcription of genes that affect the inflammatory and immune responses[[211](#_ENREF_211)], and genetic polymorphisms affecting the structure of the VDR have been associated with increased susceptibility to autoimmune hepatitis[[212](#_ENREF_212),[213](#_ENREF_213)]. Other environmental pressures related to diet, socioeconomic status, drug or alcohol abuse, sanitation, and polypharmacy have an uncertain effect on the occurrence and outcome of autoimmune hepatitis, and they warrant further assessment in population-based studies.

**FACTORS AFFECTING MAINTENANCE OR ESCALATION**

***Molecular mimicry***

Molecular mimicry between foreign and self-antigens has been proposed as a mechanism by which the adaptive immune response can be sensitized to epitopes that are similar but not identical to self[[30-33](#_ENREF_30),[214](#_ENREF_214),[215](#_ENREF_215)] (Table 3). Invading pathogens[[216-218](#_ENREF_216)], naturally occurring (environmental) antigens[[35](#_ENREF_35)], synthetic peptides (chemical agents, halothane)[[219-223](#_ENREF_219)], and vaccines[[224](#_ENREF_224),[225](#_ENREF_225)] have been implicated as xenobiotic triggers that overcome self-tolerance by generating cross-reacting antibodies and immune cells (Figure 1). The molecular mimics have structural or conformational similarities with self-antigens, and they are introduced by infection, environmental exposure, or xenobiotic modification of proteins *in situ*[[31](#_ENREF_31),[222](#_ENREF_222),[223](#_ENREF_223)].

Molecular identity rather than mimicry induces immune tolerance[[226](#_ENREF_226)], and it is a mechanism by which invading pathogens may avoid recognition and elimination by immune defenses[[227](#_ENREF_227)]. Molecular mimicry implies that the antigenic homologue is sufficiently different from the self-antigen to generate cross-reactive immune responses[[31](#_ENREF_31)]. The molecular mimic must also resemble a self-antigen with biological activity that could promote autoimmune disease[[31](#_ENREF_31)], and the structural or conformational similarities to the self-antigen must be sufficient to ensure binding to the same MHC class II molecules and activation of the same lymphocyte populations[[228](#_ENREF_228)].

Pathogenic molecular mimicry has been incriminated in diverse autoimmune diseases that have been associated with bacterial and viral infections, including rheumatic fever[[229-234](#_ENREF_229)], Guillain Barre syndrome[[235](#_ENREF_235),[236](#_ENREF_236)], Lyme disease[[237](#_ENREF_237),[238](#_ENREF_238)], Reiter’ syndrome[[239](#_ENREF_239)], ankylosing spondylitis[[240](#_ENREF_240),[241](#_ENREF_241)], rheumatoid arthritis[[242](#_ENREF_242)], multiple sclerosis[[217](#_ENREF_217)], and SLE[[243](#_ENREF_243)].

***Molecular mimicry and autoimmune hepatitis***

Molecular mimicries have been demonstrated between an autoantigen of autoimmune hepatitis (cytochrome P450 2D6) and infectious agents (Table 3). The anti-LKM1 associated with type 2 autoimmune hepatitis recognize a short-linear amino acid sequence on cytochrome P450 2D6 as its principal epitope, and antibodies to herpes simplex type 1 virus, HCV, and CMV have demonstrated cross-recognition of this epitope[[244-246](#_ENREF_244)]. Structural similarities between bacterial agents (*Escherichia coli* and *Novoshingobium aromaticivorans*) and pyruvate dehydrogenase-E2 complex (PDC-E2) have also suggested a pathogenic role for molecular mimicry in PBC[[247-251](#_ENREF_247)], and infection with a virus expressing a human P450 2D6 that is homologous to mouse P450 2D6 has induced severe liver damage in a murine model of autoimmune hepatitis[[226](#_ENREF_226),[252](#_ENREF_252)]. The main investigational challenge is to associate these molecular mimicries with pertinent pathogenic mechanisms of the disease.

***Pathogenic uncertainties and future investigations***

Studies analyzing exact peptide matches at penta-, hexa-, hepta-, and octapeptide levels have demonstrated that virtually all human proteins include a bacterial pentapeptide or hexapeptide motif[[253](#_ENREF_253)] (Table 3). Furthermore, the amino acid sequences necessary for peptide binding by MHC I and MHC II molecules are short (8-18 amino acids), and only a small portion of the antigen is required for recognition by a TCR[[254-257](#_ENREF_254)]. The relative rarity of autoimmune diseases in the general population (5%-8%)[[32](#_ENREF_32)] and low annual incidence of autoimmune hepatitis (0.85-1.9 cases per 100000 persons)[[64](#_ENREF_64)] suggest that molecular mimicry is either an unimportant cause of autoimmune hepatitis or that its impact is mitigated by mechanisms that are still undiscovered.

Molecular mimicry induced by a non-infectious environmental agent has been uncommonly described in autoimmune disease, but it has been demonstrated in PBC. Immunization of a murine model with 2-octynoic acid, a chemical used widely in cosmetic products and food flavorings[[221](#_ENREF_221),[258](#_ENREF_258),[259](#_ENREF_259)], has induced autoimmune cholangitis and antimitochondrial antibodies. The mechanism has been ascribed to a molecular mimicry in which the xenobiotic chemical has modified the lipoic binding region of PDC-E2 *in situ* and compromised immune tolerance of the self-antigen[[222](#_ENREF_222),[223](#_ENREF_223)].

Future investigations in autoimmune hepatitis should explore molecular mimicries between non-infectious environmental agents and key antigenic targets in autoimmune hepatitis, such as cytochrome P450 2D6[[244](#_ENREF_244)], formiminotransferase cyclodeaminase[[14](#_ENREF_14),[15](#_ENREF_15)], and Sep [O-phosphoserine] tRNA: Sec [selenocysteine] tRNA synthase[[260-263](#_ENREF_260)].

***Epitope spread and neo-antigens***

Autoantibodies and activated immune cells that target epitopes different from the immune-dominant epitope that initiated the immune response constitute epitope spread[[37](#_ENREF_37),[38](#_ENREF_38),[40](#_ENREF_40),[41](#_ENREF_41),[264-266](#_ENREF_264)] (Table 3). The reactivity may be against epitopes on the same molecule or homologous sequences on other molecules. Infections and environmental agents (chemicals, toxins, and drugs) may generate, amplify or sustain the autoimmune response by releasing neo-antigens directly from the injured tissue[[37](#_ENREF_37),[38](#_ENREF_38),[264](#_ENREF_264),[267](#_ENREF_267)] (Figure 1), and the neo-antigens may vary between individuals[[42](#_ENREF_42)]. The autoantibodies or immune cells activated by the neo-antigens can broaden the range of immune reactivity and promote the spread of antigenic targets[[37](#_ENREF_37),[41](#_ENREF_41),[268](#_ENREF_268),[269](#_ENREF_269)].

The initiating immune-dominant epitope may be lost during this process as the targeted homologous sequences in neighboring and remote regions become increasingly different from the original epitope[[40](#_ENREF_40)]. In this fashion, the relationship to the initial immune-dominant epitope may be lost before clinical onset of the disease, and the original invading pathogen, environmental agent, or triggering antigen may be undetectable[[270](#_ENREF_270)]. Epitope spread has been demonstrated in patients and animal models of autoimmune hepatitis characterized by antibodies to cytochrome P450 2D6[[40](#_ENREF_40)].

Epitope spread can be enhanced by endocytic processing, variability in the peptide fragments that are loaded into the class II MHC molecules, and somatic hypermutation[[35](#_ENREF_35),[41](#_ENREF_41)] (Table 3). The peptide segments loaded into the class II MHC complexes after endocytic processing can vary in length and affinity[[271](#_ENREF_271)]. Similar molecules can generate homologous peptide fragments that vary sufficiently to favor cross-reactive immune responses and thereby induce intermolecular epitope spread. Somatic hypermutation can also contribute to epitope spread by diversifying B cell receptors after antigen recognition in order to recognize a wider spectrum of foreign antigens[[41](#_ENREF_41),[266](#_ENREF_266),[272](#_ENREF_272)] (Table 3). Somatic hypermutation is an adaptive mutation involving single base substitutions mainly in the hypervariable regions of the immunoglobulin genes[[272](#_ENREF_272),[273](#_ENREF_273)]. The roles of neo-antigens and somatic hypermutation in the severity of autoimmune hepatitis have not been assessed.

***Bystander activation***

Bystander activation can increase the immune response and tissue damage by activating pre-primed T cells and spreading the damage to uninvolved neighboring cells[[274](#_ENREF_274)] (Table 3). Viral infections[[275](#_ENREF_275)], bacterial products (lipopolysaccharide)[[276](#_ENREF_276)], and virus-mimetics (vaccines)[[277](#_ENREF_277),[278](#_ENREF_278)] can induce the secretion of cytokines which in turn can stimulate the proliferation of polyclonal memory T cells. Memory CD8+ T cells are mainly affected by bystander activation, and their proliferation is mediated by interferon-gamma and interleukin (IL)-12, IL-15, and IL-18[[275](#_ENREF_275),[276](#_ENREF_276),[279](#_ENREF_279),[280](#_ENREF_280)]. Memory CD4+ T cells can also undergo bystander activation (to a lesser degree), and their proliferation is mediated mainly by IL-2[[279](#_ENREF_279),[280](#_ENREF_280)].

The bystander activation of pre-primed autoreactive T cells does not require stimulation of the TCR by a specific antigen[[279](#_ENREF_279),[281](#_ENREF_281)]. Bystander activation with the release of pro-inflammatory cytokines can intensify the collateral damage associated with microbial infection[[274](#_ENREF_274),[281-283](#_ENREF_281)], and it may be a mechanism that contributes to the emergence and progression of autoimmune disease by activating APCs and mobilizing autoreactive T cells[[274](#_ENREF_274),[279](#_ENREF_279)] (Figure 1). Bystander activation has not been assessed in autoimmune hepatitis, and the role of gut-derived microbial products in inducing a bystander effect has not been determined.

***TCR polyspecificity***

TCRs can undergo continuous rearrangements and re-combinations that broaden the range of antigens that they recognize, and this plasticity can contribute to an autoreactive response[[284](#_ENREF_284),[285](#_ENREF_285)] (Figure 1). TCRs recognize only a small portion of the peptide presented by class II MHC molecules[[254](#_ENREF_254),[256](#_ENREF_256),[257](#_ENREF_257)], and the same TCR can respond to multiple antigens[[45](#_ENREF_45),[286](#_ENREF_286)]. Polyspecificity of the TCR can generate cross-reactivity between T cells and facilitate promiscuous targeting of self-antigens.

T cell targeting can also be influenced by the surface expression of dual TCRs[[287](#_ENREF_287),[288](#_ENREF_288)] (Table 4). Thirty percent of human T cells express two functional α-chains. They may also express two β-chains at a lower frequency[[43](#_ENREF_43),[289](#_ENREF_289)]. T cells expressing dual TCRs are more difficult to stimulate[[44](#_ENREF_44)], and they may escape negative selection in the thymus by failing to demonstrate strong reactivity to self-antigens[[290](#_ENREF_290)]. In the peripheral circulation, the T cells with dual TCRs may be stimulated by foreign antigen and self-peptide, and the dual stimulation may overcome self-tolerance[[44](#_ENREF_44),[288](#_ENREF_288)]. Future investigations in autoimmune hepatitis that determine the number and nature of circulating T lymphocytes with dual TCRs may reveal a means by which to measure or monitor the autoreactive propensity.

***Intestinal dysbiosis***

The intestinal microbiome shapes the intestinal and systemic immune responses[[291-296](#_ENREF_291)] (Figure 1). Its composition varies by gender, ethnicity, age, long-term diet, and socioeconomic status[[297-300](#_ENREF_297)], and it constitutes an environmental variable that may impact on the predisposition, occurrence, and clinical phenotype of autoimmune disease. Bacterial components of the intestinal microbiome can activate Toll-like receptors (TLRs)[[296](#_ENREF_296),[301-303](#_ENREF_301)], contribute to the formation of inflammasomes[[304-307](#_ENREF_304)], stimulate the systemic immune response[[293](#_ENREF_293),[296](#_ENREF_296),[308](#_ENREF_308),[309](#_ENREF_309)], and activate immune cells within the intestine that migrate to peripheral lymphoid tissue[[310](#_ENREF_310),[311](#_ENREF_311)]. Changes in the microbial composition of the intestine (dysbiosis) have already been implicated in type 1 diabetes[[312-314](#_ENREF_312)], rheumatoid arthritis[[303](#_ENREF_303),[315-317](#_ENREF_315)], multiple sclerosis[[318](#_ENREF_318)], inflammatory bowel disease[[319-321](#_ENREF_319)], and diverse liver diseases, including NAFLD[[306](#_ENREF_306)], PBC[[249](#_ENREF_249),[322](#_ENREF_322)], PSC[[323](#_ENREF_323),[324](#_ENREF_324)], and autoimmune hepatitis[[325](#_ENREF_325),[326](#_ENREF_326)].

***Intestinal microbiome and autoimmune hepatitis***

Patients with autoimmune hepatitis have been distinguished from healthy individuals by deficiencies in the structural proteins (zona occludens 1 and occludin) that maintain integrity of the gastrointestinal mucosal barrier[[325](#_ENREF_325)] (Table 4). They also have had increased plasma levels of gut-derived bacterial lipopolysaccharide and decreased numbers of intestinal anaerobes (dysbiosis)[[325](#_ENREF_325)]. Reduced diversity and total load of gut bacteria have also been associated with exacerbations of experimental autoimmune hepatitis in HLA DRB3-positive transgenic mice[[326](#_ENREF_326)]. The findings suggest that autoimmune hepatitis is associated with dysbiosis, weakened gastrointestinal mucosal barrier, and translocation of gut-derived microbial products into the systemic circulation. The challenge is to establish the sequence of pathogenic events and distinguish causes from consequences of the liver disease.

***Intestinal microbiome and gender bias***

Autoimmune hepatitis occurs predominately in females, and this strong gender bias is evident in both children (where girls constitute 60%-76% of patients with autoimmune hepatitis) and adults (where women constitute 71%-95% of patients with autoimmune hepatitis)[[64](#_ENREF_64)]. Explanations for the female propensity for autoimmune diseases have included estrogen effects on cytokine pathways[[327](#_ENREF_327)] and gene expression[[328](#_ENREF_328)], fetal microchimerism[[329](#_ENREF_329),[330](#_ENREF_330)], and variable X-chromosomal inactivation[[331](#_ENREF_331)]. The female bias for autoimmune disease may also be explained in part by gender-specific differences in the composition of the intestinal microbiome[[300](#_ENREF_300),[332](#_ENREF_332),[333](#_ENREF_333)] (Table 4).

Commensal microbes colonizing the intestine of male non-obese diabetic mice (NOD) can raise serum testosterone levels and protect them against the development of type 1 diabetes[[300](#_ENREF_300)]. Transfer of the intestinal microbiota from mature male NOD mice to immature female NOD mice can protect the females from developing type 1 diabetes. Blockade of the androgen receptor can have a similar protective effect[[300](#_ENREF_300)]. Investigations of gender differences in the intestinal microbiome of patients with autoimmune hepatitis are needed to understand and possibly manipulate this pathogenic aspect.

***Intestinal microbiome and the “hygiene hypothesis”***

The “hygiene hypothesis” speculates that the rising risk of allergy (asthma, hay fever) and autoimmunity (type 1 diabetes, multiple sclerosis) in western countries relates to the decreasing incidence of infection and microbial exposure in childhood which in turn impairs development of the immune system[[334-337](#_ENREF_334)]. Microbial exposure can promote maturation of the immune system by stimulating TLRs, inducing Tregs, increasing production of anti-inflammatory cytokines (*e.g.*, IL-10), and generating an immune response that diminishes immune reactivity against self-antigens[[334](#_ENREF_334),[338](#_ENREF_338),[339](#_ENREF_339)].

The intestinal microbiome has emerged as a key factor in maintaining immune tolerance by allowing systemic exposure to microbial products and activated immune cells during childhood and protecting against intestinal colonization by non-commensal micro-organisms[[33](#_ENREF_33),[340](#_ENREF_340)] (Table 4). Management strategies using extracts of bacterial and parasitic components have reduced the risk of type 1 diabetes in NOD mice, and the findings suggest that manipulations of the intestinal microbiome at a young age may protect against autoimmune disease[[341](#_ENREF_341),[342](#_ENREF_342)]. The possibility that the intestinal microbiome can influence the risk, gender bias, severity, and outcome of autoimmune hepatitis is a compelling reason to investigate it further as a protective and pathogenic factor in this disease.

**TRANSITIONING FROM PATHOGENIC CONCEPTS TO NEXT GENERATION MANAGEMENT**

Translation of the pathogenic concepts into next generation management requires an understanding of each phase of autoimmune hepatitis from susceptibility to triggering events to mechanisms that sustain or intensify the inflammatory activity (Figure 2). The science of autoimmune hepatitis has not yet achieved this level of comprehension, but the opportunities to enlarge the knowledge base and impact on future management are plentiful.

Increased host susceptibility to an environmental factor is supported by genetic and epigenetic findings[[16](#_ENREF_16),[18](#_ENREF_18),[25](#_ENREF_25)], and this susceptibility may be enhanced by defects in the negative selection of autoreactive immune cells within the thymus and alterations in the intestinal microbiome[[27](#_ENREF_27),[46](#_ENREF_46),[112](#_ENREF_112)] (Figure 2). Host susceptibility can be difficult to modify, but future investigations might validate mechanisms that ensure the expression of PD-1 on thymocytes and maturing lymphocytes[[22](#_ENREF_22)], prevent or reverse DNA demethylation[[25](#_ENREF_25),[343](#_ENREF_343)], or prime the intestinal microbiome to protect against autoreactive responses[[341](#_ENREF_341),[342](#_ENREF_342)].

Progress has already been made in demonstrating that epigenetic manipulation is possible in the laboratory[[344](#_ENREF_344),[345](#_ENREF_345)]. The methyl residue on S-adenosylmethionine can silence aberrant gene expression by inhibiting DNA demethylation directly or indirectly in cell culture[[344](#_ENREF_344)]. The methyl groups donated by S-adenosylmethionine have a direct inhibitory effect on DNA demethylation, and they also impair the activity of the nuclear protein, methyl-DNA-binding domain protein 2 (MBD2). MBD2 binds specifically to methylated DNA, has demethylase activity[[89](#_ENREF_89),[346](#_ENREF_346),[347](#_ENREF_347)], and is inversely associated with DNA hypo-methylation in patients with SLE[[348](#_ENREF_348)]. Investigational interventions that alter DNA demethylation directly or indirectly by methyl group donation[[344](#_ENREF_344)] or the administration of anti-sense oligonucleotides that inhibit MBD2[[345](#_ENREF_345)] have the prospect of dampening transcriptional activity of pro-inflammatory genes and reducing susceptibility for autoimmune hepatitis.

The identification of the triggering factors for autoimmune hepatitis is a key requirement for the development of protective strategies that might include environmental modifications or specific avoidance behaviors (Figure 2). Population-based epidemiological studies that are designed to evaluate the association of infection, drugs, toxins, and xenobiotic chemicals with autoimmune hepatitis would help in identifying these triggers, and clarification of the role of the intestinal microbiome in affecting susceptibility, gender bias, and outcome could identify a modifiable source of microbial products and activated immune cells that might affect the occurrence and course of autoimmune hepatitis.

Multiple immune-mediated liver (NAFLD[[306](#_ENREF_306)], PSC[[323](#_ENREF_323),[324](#_ENREF_324)], and autoimmune hepatitis[[325](#_ENREF_325),[326](#_ENREF_326)]) and non-liver (type 1 diabetes[[313](#_ENREF_313),[314](#_ENREF_314)], rheumatoid arthritis[[303](#_ENREF_303),[315](#_ENREF_315),[316](#_ENREF_316)], multiple sclerosis[[318](#_ENREF_318)], and inflammatory bowel disease[[319-321](#_ENREF_319)]) diseases have already been linked to intestinal dysbiosis, and modifications of the intestinal microbiome by diet, probiotics, antibiotics, or re-colonization are possible[[46](#_ENREF_46)]. A preliminary randomized clinical trial of antibiotic therapy in PSC has suggested that therapy with vancomycin or metronidazole has the potential to improve liver tests and Mayo PSC risk score[[349](#_ENREF_349)], presumably by favorably altering the intestinal microbiome[[350](#_ENREF_350)].

Molecular mimicry, epitope spread, bystander activation, neo-antigen formation, TCR polyspecificity, and deficient immune inhibitory mechanisms (Tregs[[351](#_ENREF_351)] and immune inhibitory proteins[[22](#_ENREF_22)]) may extend an inciting event into a self-perpetuating autoimmune process (Figure 2). Multiple disturbances in the homeostatic pathways affecting activation[[352](#_ENREF_352)], migration[[353](#_ENREF_353)], and survival[[354](#_ENREF_354)] of T lymphocytes have already been described that may be contributory. Deficiencies in the number and function of Tregs have been implicated[[355](#_ENREF_355),[356](#_ENREF_356)] (and challenged[[357](#_ENREF_357)]), and failure of the immune inhibitory proteins, especially PD-1, to dampen the differentiation and proliferation of autoreactive cells has been an evolving area of investigational interest[[22](#_ENREF_22),[358](#_ENREF_358)]. These disturbances may in turn relate to epigenetic changes that affect the transcription of immune regulatory genes, and these genes are already being manipulated experimentally[[89](#_ENREF_89),[343](#_ENREF_343),[346](#_ENREF_346)].

Management strategies when the liver disease is established will depend on whether multiple factors must participate concurrently to sustain or escalate the disease or a predominant critical defect can be identified and targeted. Blanket immunosuppression may be necessary to suppress multiple concurrent pathogenic pathways, whereas highly specific interventions would require demonstration of a correctable pathogenic linchpin that supports the disease (Figure 2). Monoclonal antibodies against pro-inflammatory cytokines or B cells[[359](#_ENREF_359),[360](#_ENREF_360)] and recombinant molecules that dampen T cell activation by increasing expression of the immune inhibitory proteins (recombinant CTLA-4[[361-363](#_ENREF_361)] or PD-1[[364](#_ENREF_364)]) are possible supplemental therapies. The adoptive transfer of antigen-specific, induced Tregs, mesenchymal stromal cells, or myeloid-derived suppressor cells exemplifies a next-generation intervention that might replace blanket immunosuppression[[365](#_ENREF_365),[366](#_ENREF_366)].

**CONCLUSION**

Multiple pathogenic concepts have emerged to explain the susceptibility, onset, and maintenance of autoimmune hepatitis (Figure 1). Each concept is insufficient or incomplete. The risk burden for autoimmune hepatitis cannot be explained by genetic susceptibility; the triggering events of autoimmune hepatitis remain unknown; the factors that sustain or escalate the disease are unclear; and the dominant defect or particular aggregate of defects in immune homeostasis that could shape next generation therapy is unresolved.

Pathogenic concepts that are insufficient or incomplete are not wrong, and their deficiencies should drive investigations that define their impact more fully. The knowledge base of autoimmune hepatitis now includes evolving concepts of susceptibility, onset, and maintenance that should encourage investigations of acquired epigenetic change in gene expression, thymic dysfunction, molecular mimicry, epitope spread, and intestinal dysbiosis (Figure 2).

The next generation of management for autoimmune hepatitis will depend on clarification of the pathogenic sequence from susceptibility to established clinical phenotype, and it could include a strategy for prevention. Certain mechanisms may be evident throughout the course of the disease, and they may indicate a pathogenic linchpin that can be targeted selectively. Alternatively, certain mechanisms may require the alignment of several concurrent disruptions in immune homeostasis, and they may require blanket immunosuppression, possibly supplemented by site-specific interventions that target prominent contributory mechanisms. Studies that move the pathogenesis of autoimmune hepatitis closer to its cause may result in management strategies with a greater potential to replace blanket immunosuppressive regimens than interventions directed at downstream defects in the homeostatic network which are likely to yield supplemental rather than replacement interventions.

**REFERENCES**

1 **Alvarez F**, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Büschenfelde KH, Zeniya M. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. *J Hepatol* 1999; **31**: 929-938 [PMID: 10580593 DOI: 10.1016/S0168-8278(99)80297-9]

2 **Manns MP**, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM; American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. *Hepatology* 2010; **51**: 2193-2213 [PMID: 20513004 DOI: 10.1002/hep.23584]

3 **Czaja AJ**, Manns MP. The validity and importance of subtypes in autoimmune hepatitis: a point of view. *Am J Gastroenterol* 1995; **90**: 1206-1211 [PMID: 7639216]

4 **Czaja AJ**. Performance parameters of the conventional serological markers for autoimmune hepatitis. *Dig Dis Sci* 2011; **56**: 545-554 [PMID: 21127976 DOI: 10.1007/s10620-010-1501-1]

5 **Czaja AJ**, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. *Hepatology* 1996; **24**: 1068-1073 [PMID: 8903377 DOI: 10.1002/hep.510240515]

6 **Chretien-Leprince P**, Ballot E, Andre C, Olsson NO, Fabien N, Escande A, Oksman F, Dubuquoi S, Jego S, Goetz J, Chevailler A, Sanmarco M, Humbel RL, Johanet C. Diagnostic value of anti-F-actin antibodies in a French multicenter study. *Ann N Y Acad Sci* 2005; **1050**: 266-273 [PMID: 16014542 DOI: 10.1196/annals.1313.028]

7 **Frenzel C**, Herkel J, Lüth S, Galle PR, Schramm C, Lohse AW. Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. *Am J Gastroenterol* 2006; **101**: 2731-2736 [PMID: 17227520 DOI: 10.1111/j.1572-0241.2006.00830.x]

8 **Couto CA**, Bittencourt PL, Porta G, Abrantes-Lemos CP, Carrilho FJ, Guardia BD, Cançado EL. Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis. *Hepatology* 2014; **59**: 592-600 [PMID: 23929663 DOI: 10.1002/hep.26666]

9 **Manns M**, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Büschenfelde KH. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. *Lancet* 1987; **1**: 292-294 [PMID: 2880112 DOI: 10.1016/S0140-6736(87)92024-1]

10 **Montano-Loza AJ**, Shums Z, Norman GL, Czaja AJ. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. *Liver Int* 2012; **32**: 85-92 [PMID: 21745277 DOI: 10.1111/j.1478-3231.2011.02502.x]

11 **Targan SR**, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. *Gastroenterology* 1995; **108**: 1159-1166 [PMID: 7698584 DOI: 10.1016/0016-5085(95)90215-5]

12 **Zauli D**, Ghetti S, Grassi A, Descovich C, Cassani F, Ballardini G, Muratori L, Bianchi FB. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. *Hepatology* 1997; **25**: 1105-1107 [PMID: 9141425 DOI: 10.1002/hep.510250510]

13 **Abuaf N**, Johanet C, Chretien P, Martini E, Soulier E, Laperche S, Homberg JC. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. *Hepatology* 1992; **16**: 892-898 [PMID: 1398495 DOI: 10.1002/hep.1840160407]

14 **Lapierre P**, Hajoui O, Homberg JC, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. *Gastroenterology* 1999; **116**: 643-649 [PMID: 10029623 DOI: 10.1016/S0016-5085(99)70186-1]

15 **Muratori L**, Sztul E, Muratori P, Gao Y, Ripalti A, Ponti C, Lenzi M, Landini MP, Bianchi FB. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. *Hepatology* 2001; **34**: 494-501 [PMID: 11526534 DOI: 10.1053/jhep.2001.27179]

16 **Strettell MD**, Donaldson PT, Thomson LJ, Santrach PJ, Moore SB, Czaja AJ, Williams R. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. *Gastroenterology* 1997; **112**: 2028-2035 [PMID: 9178696 DOI: 10.1053/gast.1997.v112.pm9178696]

17 **Czaja AJ**. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. *Clin Gastroenterol Hepatol* 2008; **6**: 379-388 [PMID: 18328791 DOI: 10.1016/j.cgh.2007.12.048]

18 **van Gerven NM**, de Boer YS, Zwiers A, Verwer BJ, Drenth JP, van Hoek B, van Erpecum KJ, Beuers U, van Buuren HR, den Ouden JW, Verdonk RC, Koek GH, Brouwer JT, Guichelaar MM, Vrolijk JM, Coenraad MJ, Kraal G, Mulder CJ, van Nieuwkerk CM, Bloemena E, Verspaget HW, Kumar V, Zhernakova A, Wijmenga C, Franke L, Bouma G; Dutch Autoimmune Hepatitis Study Group. HLA-DRB1\*03:01 and HLA-DRB1\*04:01 modify the presentation and outcome in autoimmune hepatitis type-1. *Genes Immun* 2015; **16**: 247-252 [PMID: 25611558 DOI: 10.1038/gene.2014.82]

19 **Czaja AJ**. Transitioning from Idiopathic to Explainable Autoimmune Hepatitis. *Dig Dis Sci* 2015; **60**: 2881-2900 [PMID: 25999246 DOI: 10.1007/s10620-015-3708-7]

20 **Liberal R**, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: From mechanisms to therapy. *Rev Clin Esp* 2016; **216**: 372-383 [PMID: 27161382 DOI: 10.1016/j.rce.2016.04.003]

21 **Mieli-Vergani G**, Vergani D, Czaja AJ, Manns MP, Krawitt EL, Vierling JM, Lohse AW, Montano-Loza AJ. Autoimmune hepatitis. *Nat Rev Dis Primers* 2018; **4**: 18017 [PMID: 29644994 DOI: 10.1038/nrdp.2018.17]

22 **Czaja AJ**. Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. *Autoimmunity* 2019; **52**: 144-160 [PMID: 31298041 DOI: 10.1080/08916934.2019.1641200]

23 **Webb GJ**, Hirschfield GM. Using GWAS to identify genetic predisposition in hepatic autoimmunity. *J Autoimmun* 2016; **66**: 25-39 [PMID: 26347073 DOI: 10.1016/j.jaut.2015.08.016]

24 **Czaja AJ**. Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management. *Dig Dis Sci* 2018; **63**: 1706-1725 [PMID: 29671161 DOI: 10.1007/s10620-018-5072-x]

25 **Czaja AJ**. Epigenetic changes and their implications in autoimmune hepatitis. *Eur J Clin Invest* 2018; **48**: [PMID: 29383703 DOI: 10.1111/eci.12899]

26 **Mann DA**. Epigenetics in liver disease. *Hepatology* 2014; **60**: 1418-1425 [PMID: 24633972 DOI: 10.1002/hep.27131]

27 **Robey E**, Fowlkes BJ. Selective events in T cell development. *Annu Rev Immunol* 1994; **12**: 675-705 [PMID: 8011294 DOI: 10.1146/annurev.iy.12.040194.003331]

28 **Nossal GJ**. Negative selection of lymphocytes. *Cell* 1994; **76**: 229-239 [PMID: 8293461 DOI: 10.1016/0092-8674(94)90331-X]

29 **Eichmann K**. A signal strength hypothesis of thymic selection: preliminary considerations. *Immunol Lett* 1995; **44**: 87-90 [PMID: 7797260 DOI: 10.1016/0165-2478(94)00197-Y]

30 **Cusick MF**, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. *Clin Rev Allergy Immunol* 2012; **42**: 102-111 [PMID: 22095454 DOI: 10.1007/s12016-011-8293-8]

31 **Oldstone MB**. Molecular mimicry: its evolution from concept to mechanism as a cause of autoimmune diseases. *Monoclon Antib Immunodiagn Immunother* 2014; **33**: 158-165 [PMID: 24694269 DOI: 10.1089/mab.2013.0090]

32 **Rose NR**. Molecular mimicry and clonal deletion: A fresh look. *J Theor Biol* 2015; **375**: 71-76 [PMID: 25172771 DOI: 10.1016/j.jtbi.2014.08.034]

33 **Rojas M**, Restrepo-Jiménez P, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Ramírez-Santana C, Leung PSC, Ansari AA, Gershwin ME, Anaya JM. Molecular mimicry and autoimmunity. *J Autoimmun* 2018; **95**: 100-123 [PMID: 30509385 DOI: 10.1016/j.jaut.2018.10.012]

34 **Getts DR**, Chastain EM, Terry RL, Miller SD. Virus infection, antiviral immunity, and autoimmunity. *Immunol Rev* 2013; **255**: 197-209 [PMID: 23947356 DOI: 10.1111/imr.12091]

35 **Floreani A**, Leung PS, Gershwin ME. Environmental Basis of Autoimmunity. *Clin Rev Allergy Immunol* 2016; **50**: 287-300 [PMID: 25998909 DOI: 10.1007/s12016-015-8493-8]

36 **Vogel A**, Manns MP, Strassburg CP. Autoimmunity and viruses. *Clin Liver Dis* 2002; **6**: 739-753 [PMID: 12362578 DOI: 10.1016/S1089-3261(02)00024-7]

37 **Vanderlugt CJ**, Miller SD. Epitope spreading. *Curr Opin Immunol* 1996; **8**: 831-836 [PMID: 8994863 DOI: 10.1016/S0952-7915(96)80012-4]

38 **Vanderlugt CL**, Begolka WS, Neville KL, Katz-Levy Y, Howard LM, Eagar TN, Bluestone JA, Miller SD. The functional significance of epitope spreading and its regulation by co-stimulatory molecules. *Immunol Rev* 1998; **164**: 63-72 [PMID: 9795764 DOI: 10.1111/j.1600-065X.1998.tb01208.x]

39 **Tsunoda I**, Libbey JE, Fujinami RS. Sequential polymicrobial infections lead to CNS inflammatory disease: possible involvement of bystander activation in heterologous immunity. *J Neuroimmunol* 2007; **188**: 22-33 [PMID: 17604850 DOI: 10.1016/j.jneuroim.2007.05.012]

40 **Hintermann E**, Holdener M, Bayer M, Loges S, Pfeilschifter JM, Granier C, Manns MP, Christen U. Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model. *J Autoimmun* 2011; **37**: 242-253 [PMID: 21795021 DOI: 10.1016/j.jaut.2011.06.005]

41 **Cornaby C**, Gibbons L, Mayhew V, Sloan CS, Welling A, Poole BD. B cell epitope spreading: mechanisms and contribution to autoimmune diseases. *Immunol Lett* 2015; **163**: 56-68 [PMID: 25445494 DOI: 10.1016/j.imlet.2014.11.001]

42 **Rosen A**, Casciola-Rosen L. Autoantigens in systemic autoimmunity: critical partner in pathogenesis. *J Intern Med* 2009; **265**: 625-631 [PMID: 19493056 DOI: 10.1111/j.1365-2796.2009.02102.x]

43 **Padovan E**, Casorati G, Dellabona P, Meyer S, Brockhaus M, Lanzavecchia A. Expression of two T cell receptor alpha chains: dual receptor T cells. *Science* 1993; **262**: 422-424 [PMID: 8211163 DOI: 10.1126/science.8211163]

44 **Blichfeldt E**, Munthe LA, Røtnes JS, Bogen B. Dual T cell receptor T cells have a decreased sensitivity to physiological ligands due to reduced density of each T cell receptor. *Eur J Immunol* 1996; **26**: 2876-2884 [PMID: 8977280 DOI: 10.1002/eji.1830261211]

45 **Wucherpfennig KW**, Allen PM, Celada F, Cohen IR, De Boer R, Garcia KC, Goldstein B, Greenspan R, Hafler D, Hodgkin P, Huseby ES, Krakauer DC, Nemazee D, Perelson AS, Pinilla C, Strong RK, Sercarz EE. Polyspecificity of T cell and B cell receptor recognition. *Semin Immunol* 2007; **19**: 216-224 [PMID: 17398114 DOI: 10.1016/j.smim.2007.02.012]

46 **Czaja AJ**. Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis. *World J Gastroenterol* 2016; **22**: 9257-9278 [PMID: 27895415 DOI: 10.3748/wjg.v22.i42.9257]

47 **Czaja AJ**, Strettell MD, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT, Williams R. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. *Hepatology* 1997; **25**: 317-323 [PMID: 9021941 DOI: 10.1002/hep.510250211]

48 **Czaja AJ**, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. *Gastroenterology* 1999; **117**: 645-652 [PMID: 10464141 DOI: 10.1016/S0016-5085(99)70458-0]

49 **Seki T**, Kiyosawa K, Inoko H, Ota M. Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. *Hepatology* 1990; **12**: 1300-1304 [PMID: 2175292 DOI: 10.1002/hep.1840120609]

50 **Goldberg AC**, Bittencourt PL, Mougin B, Cançado EL, Porta G, Carrilho F, Kalil J. Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. *Hum Immunol* 2001; **62**: 165-169 [PMID: 11182227 DOI: 10.1016/S0198-8859(00)00234-2]

51 **Qiu DK**, Ma X. Relationship between human leukocyte antigen-DRB1 and autoimmune hepatitis type I in Chinese patients. *J Gastroenterol Hepatol* 2003; **18**: 63-67 [PMID: 12519226 DOI: 10.1046/j.1440-1746.2003.02918.x]

52 **Vázquez-García MN**, Aláez C, Olivo A, Debaz H, Pérez-Luque E, Burguete A, Cano S, de la Rosa G, Bautista N, Hernández A, Bandera J, Torres LF, Kershenobich D, Alvarez F, Gorodezky C. MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. *J Hepatol* 1998; **28**: 985-990 [PMID: 9672174 DOI: 10.1016/S0168-8278(98)80347-4]

53 **Czaja AJ**, Souto EO, Bittencourt PL, Cancado EL, Porta G, Goldberg AC, Donaldson PT. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. *J Hepatol* 2002; **37**: 302-308 [PMID: 12175624 DOI: 10.1016/S0168-8278(02)00182-4]

54 **Fortes Mdel P**, Machado IV, Gil G, Fernández-Mestre M, Dagher L, León RV, Bianco NE, Tassinari P. Genetic contribution of major histocompatibility complex class II region to type 1 autoimmune hepatitis susceptibility in Venezuela. *Liver Int* 2007; **27**: 1409-1416 [PMID: 17927716 DOI: 10.1111/j.1478-3231.2007.01581.x]

55 **Lim YS**, Oh HB, Choi SE, Kwon OJ, Heo YS, Lee HC, Suh DJ. Susceptibility to type 1 autoimmune hepatitis is associated with shared amino acid sequences at positions 70-74 of the HLA-DRB1 molecule. *J Hepatol* 2008; **48**: 133-139 [PMID: 18022727 DOI: 10.1016/j.jhep.2007.08.019]

56 **Chaouali M**, Carvalho A, Tezeghdenti A, Ben Azaiez M, Cunha C, Ghazouani E, Kochkar R. Cytotoxic T lymphocyte antigen-4 gene polymorphisms and susceptibility to type 1 autoimmune hepatitis in the Tunisian population. *Genes Dis* 2018; **5**: 256-262 [PMID: 30320190 DOI: 10.1016/j.gendis.2017.12.006]

57 **Czaja AJ**, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. *Hepatology* 2006; **43**: 532-538 [PMID: 16496338 DOI: 10.1002/hep.21074]

58 **Pando M**, Larriba J, Fernandez GC, Fainboim H, Ciocca M, Ramonet M, Badia I, Daruich J, Findor J, Tanno H, Cañero-Velasco C, Fainboim L. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. *Hepatology* 1999; **30**: 1374-1380 [PMID: 10573514 DOI: 10.1002/hep.510300611]

59 **Czaja AJ**, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. *Immunol Rev* 2000; **174**: 250-259 [PMID: 10807521 DOI: 10.1034/j.1600-0528.2002.017401.x]

60 **Agarwal K**, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. *Hepatology* 2000; **31**: 49-53 [PMID: 10613727 DOI: 10.1002/hep.510310110]

61 **Agarwal K**, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. *Tissue Antigens* 2007; **69**: 227-235 [PMID: 17493146 DOI: 10.1111/j.1399-0039.2006.00794.x]

62 **Cookson S**, Constantini PK, Clare M, Underhill JA, Bernal W, Czaja AJ, Donaldson PT. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. *Hepatology* 1999; **30**: 851-856 [PMID: 10498633 DOI: 10.1002/hep.510300412]

63 **Muratori P**, Czaja AJ, Muratori L, Pappas G, Maccariello S, Cassani F, Granito A, Ferrari R, Mantovani V, Lenzi M, Bianchi FB. Genetic distinctions between autoimmune hepatitis in Italy and North America. *World J Gastroenterol* 2005; **11**: 1862-1866 [PMID: 15793882 DOI: 10.3748/wjg.v11.i12.1862]

64 **Czaja AJ**. Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis. *Dig Dis Sci* 2017; **62**: 2277-2292 [PMID: 28710658 DOI: 10.1007/s10620-017-4675-y]

65 **de Boer YS**, van Gerven NM, Zwiers A, Verwer BJ, van Hoek B, van Erpecum KJ, Beuers U, van Buuren HR, Drenth JP, den Ouden JW, Verdonk RC, Koek GH, Brouwer JT, Guichelaar MM, Vrolijk JM, Kraal G, Mulder CJ, van Nieuwkerk CM, Fischer J, Berg T, Stickel F, Sarrazin C, Schramm C, Lohse AW, Weiler-Normann C, Lerch MM, Nauck M, Völzke H, Homuth G, Bloemena E, Verspaget HW, Kumar V, Zhernakova A, Wijmenga C, Franke L, Bouma G; Dutch Autoimmune Hepatitis Study Group; LifeLines Cohort Study; Study of Health in Pomerania. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. *Gastroenterology* 2014; **147**: 443-52.e5 [PMID: 24768677 DOI: 10.1053/j.gastro.2014.04.022]

66 **Agarwal K**, Jones DE, Daly AK, James OF, Vaidya B, Pearce S, Bassendine MF. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. *J Hepatol* 2000; **32**: 538-541 [PMID: 10782900 DOI: 10.1016/S0168-8278(00)80213-5]

67 **Jeffries MA**, Sawalha AH. Autoimmune disease in the epigenetic era: how has epigenetics changed our understanding of disease and how can we expect the field to evolve? *Expert Rev Clin Immunol* 2015; **11**: 45-58 [PMID: 25534978 DOI: 10.1586/1744666X.2015.994507]

68 **Sydow JF**, Cramer P. RNA polymerase fidelity and transcriptional proofreading. *Curr Opin Struct Biol* 2009; **19**: 732-739 [PMID: 19914059 DOI: 10.1016/j.sbi.2009.10.009]

69 **Tough DF**, Prinjha RK. Immune disease-associated variants in gene enhancers point to BET epigenetic mechanisms for therapeutic intervention. *Epigenomics* 2017; **9**: 573-584 [PMID: 27925476 DOI: 10.2217/epi-2016-0144]

70 **Campanero MR**, Armstrong MI, Flemington EK. CpG methylation as a mechanism for the regulation of E2F activity. *Proc Natl Acad Sci USA* 2000; **97**: 6481-6486 [PMID: 10823896 DOI: 10.1073/pnas.100340697]

71 **Kouzarides T**. Chromatin modifications and their function. *Cell* 2007; **128**: 693-705 [PMID: 17320507 DOI: 10.1016/j.cell.2007.02.005]

72 **Black JC**, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. *Mol Cell* 2012; **48**: 491-507 [PMID: 23200123 DOI: 10.1016/j.molcel.2012.11.006]

73 **Ambros V**. microRNAs: tiny regulators with great potential. *Cell* 2001; **107**: 823-826 [PMID: 11779458 DOI: 10.1016/S0092-8674(01)00616-X]

74 **Ambros V**. The functions of animal microRNAs. *Nature* 2004; **431**: 350-355 [PMID: 15372042 DOI: 10.1038/nature02871]

75 **Filipowicz W**, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? *Nat Rev Genet* 2008; **9**: 102-114 [PMID: 18197166 DOI: 10.1038/nrg2290]

76 **Iborra M**, Bernuzzi F, Invernizzi P, Danese S. MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. *Autoimmun Rev* 2012; **11**: 305-314 [PMID: 20627134 DOI: 10.1016/j.autrev.2010.07.002]

77 **Cedar H**, Bergman Y. Programming of DNA methylation patterns. *Annu Rev Biochem* 2012; **81**: 97-117 [PMID: 22404632 DOI: 10.1146/annurev-biochem-052610-091920]

78 **Schomacher L**. Mammalian DNA demethylation: multiple faces and upstream regulation. *Epigenetics* 2013; **8**: 679-684 [PMID: 23803967 DOI: 10.4161/epi.24977]

79 **Tahiliani M**, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, Rao A. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. *Science* 2009; **324**: 930-935 [PMID: 19372391 DOI: 10.1126/science.1170116]

80 **Guo JU**, Su Y, Zhong C, Ming GL, Song H. Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. *Cell Cycle* 2011; **10**: 2662-2668 [PMID: 21811096 DOI: 10.4161/cc.10.16.17093]

81 **Kohli RM**, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. *Nature* 2013; **502**: 472-479 [PMID: 24153300 DOI: 10.1038/nature12750]

82 **Javierre BM**, Fernandez AF, Richter J, Al-Shahrour F, Martin-Subero JI, Rodriguez-Ubreva J, Berdasco M, Fraga MF, O'Hanlon TP, Rider LG, Jacinto FV, Lopez-Longo FJ, Dopazo J, Forn M, Peinado MA, Carreño L, Sawalha AH, Harley JB, Siebert R, Esteller M, Miller FW, Ballestar E. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. *Genome Res* 2010; **20**: 170-179 [PMID: 20028698 DOI: 10.1101/gr.100289.109]

83 **Coit P**, Jeffries M, Altorok N, Dozmorov MG, Koelsch KA, Wren JD, Merrill JT, McCune WJ, Sawalha AH. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naïve CD4+ T cells from lupus patients. *J Autoimmun* 2013; **43**: 78-84 [PMID: 23623029 DOI: 10.1016/j.jaut.2013.04.003]

84 **Lleo A**, Zhang W, Zhao M, Tan Y, Bernuzzi F, Zhu B, Liu Q, Tan Q, Malinverno F, Valenti L, Jiang T, Tan L, Liao W, Coppel R, Invernizzi P, Lu Q, Adams DH, Gershwin ME; PBC Epigenetic Study Group. DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis. *Clin Epigenetics* 2015; **7**: 61 [PMID: 26150899 DOI: 10.1186/s13148-015-0098-9]

85 **Javierre BM**, Hernando H, Ballestar E. Environmental triggers and epigenetic deregulation in autoimmune disease. *Discov Med* 2011; **12**: 535-545 [PMID: 22204770]

86 **Osley MA**, Fleming AB, Kao CF. Histone ubiquitylation and the regulation of transcription. *Results Probl Cell Differ* 2006; **41**: 47-75 [PMID: 16909890 DOI: 10.1007/400\_006]

87 **Wysocka J**, Allis CD, Coonrod S. Histone arginine methylation and its dynamic regulation. *Front Biosci* 2006; **11**: 344-355 [PMID: 16146736 DOI: 10.2741/1802]

88 **Tao R**, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, Li B, Turka LA, Olson EN, Greene MI, Wells AD, Hancock WW. Deacetylase inhibition promotes the generation and function of regulatory T cells. *Nat Med* 2007; **13**: 1299-1307 [PMID: 17922010 DOI: 10.1038/nm1652]

89 **Szyf M**. Epigenetic therapeutics in autoimmune disease. *Clin Rev Allergy Immunol* 2010; **39**: 62-77 [PMID: 19644776 DOI: 10.1007/s12016-009-8172-8]

90 **Gregory PD**, Wagner K, Hörz W. Histone acetylation and chromatin remodeling. *Exp Cell Res* 2001; **265**: 195-202 [PMID: 11302684 DOI: 10.1006/excr.2001.5187]

91 **de Ruijter AJ**, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. *Biochem J* 2003; **370**: 737-749 [PMID: 12429021 DOI: 10.1042/BJ20021321]

92 **Thiagalingam S**, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. *Ann N Y Acad Sci* 2003; **983**: 84-100 [PMID: 12724214 DOI: 10.1111/j.1749-6632.2003.tb05964.x]

93 **Hu N**, Qiu X, Luo Y, Yuan J, Li Y, Lei W, Zhang G, Zhou Y, Su Y, Lu Q. Abnormal histone modification patterns in lupus CD4+ T cells. *J Rheumatol* 2008; **35**: 804-810 [PMID: 18398941]

94 **Mercer TR**, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. *Nat Rev Genet* 2009; **10**: 155-159 [PMID: 19188922 DOI: 10.1038/nrg2521]

95 **Xiao C**, Rajewsky K. MicroRNA control in the immune system: basic principles. *Cell* 2009; **136**: 26-36 [PMID: 19135886 DOI: 10.1016/j.cell.2008.12.027]

96 **Pratt AJ**, MacRae IJ. The RNA-induced silencing complex: a versatile gene-silencing machine. *J Biol Chem* 2009; **284**: 17897-17901 [PMID: 19342379 DOI: 10.1074/jbc.R900012200]

97 **Chen X**, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. *Cell Res* 2008; **18**: 997-1006 [PMID: 18766170 DOI: 10.1038/cr.2008.282]

98 **Hoefig KP**, Heissmeyer V. MicroRNAs grow up in the immune system. *Curr Opin Immunol* 2008; **20**: 281-287 [PMID: 18554884 DOI: 10.1016/j.coi.2008.05.005]

99 **Bi Y**, Liu G, Yang R. MicroRNAs: novel regulators during the immune response. *J Cell Physiol* 2009; **218**: 467-472 [PMID: 19034913 DOI: 10.1002/jcp.21639]

100 **Harris A**, Krams SM, Martinez OM. MicroRNAs as immune regulators: implications for transplantation. *Am J Transplant* 2010; **10**: 713-719 [PMID: 20199506 DOI: 10.1111/j.1600-6143.2010.03032.x]

101 **Tomankova T**, Petrek M, Gallo J, Kriegova E. MicroRNAs: Emerging Regulators of Immune-Mediated Diseases. *Scand J Immunol* 2012; **75**: 129-141 [PMID: 21988491 DOI: 10.1111/j.1365-3083.2011.02650.x]

102 **Haider BA**, Baras AS, McCall MN, Hertel JA, Cornish TC, Halushka MK. A critical evaluation of microRNA biomarkers in non-neoplastic disease. *PLoS One* 2014; **9**: e89565 [PMID: 24586876 DOI: 10.1371/journal.pone.0089565]

103 **Migita K**, Komori A, Kozuru H, Jiuchi Y, Nakamura M, Yasunami M, Furukawa H, Abiru S, Yamasaki K, Nagaoka S, Hashimoto S, Bekki S, Kamitsukasa H, Nakamura Y, Ohta H, Shimada M, Takahashi H, Mita E, Hijioka T, Yamashita H, Kouno H, Nakamuta M, Ario K, Muro T, Sakai H, Sugi K, Nishimura H, Yoshizawa K, Sato T, Naganuma A, Komatsu T, Oohara Y, Makita F, Tomizawa M, Yatsuhashi H. Circulating microRNA Profiles in Patients with Type-1 Autoimmune Hepatitis. *PLoS One* 2015; **10**: e0136908 [PMID: 26575387 DOI: 10.1371/journal.pone.0136908]

104 **Frankel LB**, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. *J Biol Chem* 2008; **283**: 1026-1033 [PMID: 17991735 DOI: 10.1074/jbc.M707224200]

105 **Ando Y**, Yang GX, Kenny TP, Kawata K, Zhang W, Huang W, Leung PS, Lian ZX, Okazaki K, Ansari AA, He XS, Invernizzi P, Ridgway WM, Lu Q, Gershwin ME. Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-β receptor type II mouse. *J Autoimmun* 2013; **41**: 111-119 [PMID: 23395552 DOI: 10.1016/j.jaut.2012.12.013]

106 **Adkins B**, Mueller C, Okada CY, Reichert RA, Weissman IL, Spangrude GJ. Early events in T-cell maturation. *Annu Rev Immunol* 1987; **5**: 325-365 [PMID: 3109456 DOI: 10.1146/annurev.iy.05.040187.001545]

107 **Godfrey DI**, Zlotnik A. Control points in early T-cell development. *Immunol Today* 1993; **14**: 547-553 [PMID: 7903854 DOI: 10.1016/0167-5699(93)90186-O]

108 **von Boehmer H**, Aifantis I, Azogui O, Feinberg J, Saint-Ruf C, Zober C, Garcia C, Buer J. Crucial function of the pre-T-cell receptor (TCR) in TCR beta selection, TCR beta allelic exclusion and alpha beta versus gamma delta lineage commitment. *Immunol Rev* 1998; **165**: 111-119 [PMID: 9850856 DOI: 10.1111/j.1600-065X.1998.tb01234.x]

109 **Nishimura H**, Honjo T, Minato N. Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice. *J Exp Med* 2000; **191**: 891-898 [PMID: 10704469 DOI: 10.1084/jem.191.5.891]

110 **von Boehmer H**. Developmental biology of T cells in T cell-receptor transgenic mice. *Annu Rev Immunol* 1990; **8**: 531-556 [PMID: 2188673 DOI: 10.1146/annurev.iy.08.040190.002531]

111 **von Boehmer H**. Positive selection of lymphocytes. *Cell* 1994; **76**: 219-228 [PMID: 8293460 DOI: 10.1016/0092-8674(94)90330-1]

112 **Jiang TT**, Martinov T, Xin L, Kinder JM, Spanier JA, Fife BT, Way SS. Programmed Death-1 Culls Peripheral Accumulation of High-Affinity Autoreactive CD4 T Cells to Protect against Autoimmunity. *Cell Rep* 2016; **17**: 1783-1794 [PMID: 27829150 DOI: 10.1016/j.celrep.2016.10.042]

113 **Hsieh CS**, Zheng Y, Liang Y, Fontenot JD, Rudensky AY. An intersection between the self-reactive regulatory and nonregulatory T cell receptor repertoires. *Nat Immunol* 2006; **7**: 401-410 [PMID: 16532000 DOI: 10.1038/ni1318]

114 **Moon JJ**, Dash P, Oguin TH 3rd, McClaren JL, Chu HH, Thomas PG, Jenkins MK. Quantitative impact of thymic selection on Foxp3+ and Foxp3- subsets of self-peptide/MHC class II-specific CD4+ T cells. *Proc Natl Acad Sci USA* 2011; **108**: 14602-14607 [PMID: 21873213 DOI: 10.1073/pnas.1109806108]

115 **Bautista JL**, Lio CW, Lathrop SK, Forbush K, Liang Y, Luo J, Rudensky AY, Hsieh CS. Intraclonal competition limits the fate determination of regulatory T cells in the thymus. *Nat Immunol* 2009; **10**: 610-617 [PMID: 19430476 DOI: 10.1038/ni.1739]

116 **Blank C**, Brown I, Marks R, Nishimura H, Honjo T, Gajewski TF. Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. *J Immunol* 2003; **171**: 4574-4581 [PMID: 14568931 DOI: 10.4049/jimmunol.171.9.4574]

117 **Nielsen C**, Ohm-Laursen L, Barington T, Husby S, Lillevang ST. Alternative splice variants of the human PD-1 gene. *Cell Immunol* 2005; **235**: 109-116 [PMID: 16171790 DOI: 10.1016/j.cellimm.2005.07.007]

118 **Pen JJ**, Keersmaecker BD, Heirman C, Corthals J, Liechtenstein T, Escors D, Thielemans K, Breckpot K. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. *Gene Ther* 2014; **21**: 262-271 [PMID: 24401835 DOI: 10.1038/gt.2013.80]

119 **Guo Y**, Walsh AM, Canavan M, Wechalekar MD, Cole S, Yin X, Scott B, Loza M, Orr C, McGarry T, Bombardieri M, Humby F, Proudman SM, Pitzalis C, Smith MD, Friedman JR, Anderson I, Madakamutil L, Veale DJ, Fearon U, Nagpal S. Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. *PLoS One* 2018; **13**: e0192704 [PMID: 29489833 DOI: 10.1371/journal.pone.0192704]

120 **Vento S**, Garofano T, Di Perri G, Dolci L, Concia E, Bassetti D. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. *Lancet* 1991; **337**: 1183-1187 [PMID: 1673738 DOI: 10.1016/0140-6736(91)92858-Y]

121 **Huppertz HI**, Treichel U, Gassel AM, Jeschke R, Meyer zum Büschenfelde KH. Autoimmune hepatitis following hepatitis A virus infection. *J Hepatol* 1995; **23**: 204-208 [PMID: 7499793 DOI: 10.1016/0168-8278(95)80336-X]

122 **Hilzenrat N**, Zilberman D, Klein T, Zur B, Sikuler E. Autoimmune hepatitis in a genetically susceptible patient: is it triggered by acute viral hepatitis A? *Dig Dis Sci* 1999; **44**: 1950-1952 [PMID: 10548341 DOI: 10.1023/a:1026645629103]

123 **Grünhage F**, Spengler U, Fischer HP, Sauerbruch T. Autoimmune hepatitis--sequel of a relapsing hepatitis A in a 75-year-old woman. *Digestion* 2004; **70**: 187-191 [PMID: 15557764 DOI: 10.1159/000082253]

124 **Tabak F**, Ozdemir F, Tabak O, Erer B, Tahan V, Ozaras R. Autoimmune hepatitis induced by the prolonged hepatitis A virus infection. *Ann Hepatol* 2008; **7**: 177-179 [PMID: 18626439 DOI: 10.1016/S1665-2681(19)31878-2]

125 **Kim YD**, Kim KA, Rou WS, Lee JS, Song TJ, Bae WK, Kim NH. [A case of autoimmune hepatitis following acute hepatitis A]. *Korean J Gastroenterol* 2011; **57**: 315-318 [PMID: 21623141 DOI: 10.4166/kjg.2011.57.5.315]

126 **Laskus T**, Slusarczyk J. Autoimmune chronic active hepatitis developing after acute type B hepatitis. *Dig Dis Sci* 1989; **34**: 1294-1297 [PMID: 2752878 DOI: 10.1007/BF01537282]

127 **Vento S**, Cainelli F, Renzini C, Concia E. Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance. *Lancet* 1997; **350**: 1298-1299 [PMID: 9357416 DOI: 10.1016/S0140-6736(05)62476-2]

128 **Vento S**, Guella L, Mirandola F, Cainelli F, Di Perri G, Solbiati M, Ferraro T, Concia E. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. *Lancet* 1995; **346**: 608-609 [PMID: 7651006 DOI: 10.1016/S0140-6736(95)91438-2]

129 **Kojima K**, Nagayama R, Hirama S, Maeda T, Takikawa H, Miyake K, Yamanaka M, Shiga J. Epstein-Barr virus infection resembling autoimmune hepatitis with lactate dehydrogenase and alkaline phosphatase anomaly. *J Gastroenterol* 1999; **34**: 706-712 [PMID: 10588189 DOI: 10.1007/s005350050324]

130 **Nobili V**, Comparcola D, Sartorelli MR, Devito R, Marcellini M. Autoimmune hepatitis type 1 after Epstein-Barr virus infection. *Pediatr Infect Dis J* 2003; **22**: 387 [PMID: 12690282 DOI: 10.1097/01.inf.0000060825.68086.9c]

131 **Cabibi D**. Autoimmune hepatitis following Epstein-Barr virus infection. *BMJ Case Rep* 2008; **2008**: bcr0620080071 [PMID: 21716814 DOI: 10.1136/bcr.06.2008.0071]

132 **Zellos A**, Spoulou V, Roma-Giannikou E, Karentzou O, Dalekos GN, Theodoridou M. Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: art of facts or an artifact? *Ann Hepatol* 2013; **12**: 147-151 [PMID: 23293207 DOI: 10.1016/S1665-2681(19)31398-5]

133 **Al-Hamoudi WK**. Severe autoimmune hepatitis triggered by varicella zoster infection. *World J Gastroenterol* 2009; **15**: 1004-1006 [PMID: 19248202 DOI: 10.3748/wjg.15.1004]

134 **Hagel S**, Bruns T, Herrmann A, Tannapfel A, Stallmach A. Autoimmune hepatitis in an HIV-infected patient: an intriguing association. *Int J STD AIDS* 2012; **23**: 448-450 [PMID: 22807544 DOI: 10.1258/ijsa.2009.009337]

135 **Lenzi M**, Ballardini G, Fusconi M, Cassani F, Selleri L, Volta U, Zauli D, Bianchi FB. Type 2 autoimmune hepatitis and hepatitis C virus infection. *Lancet* 1990; **335**: 258-259 [PMID: 1967721 DOI: 10.1016/0140-6736(90)90070-l]

136 **Czaja AJ**, Taswell HF, Rakela J, Schimek CM. Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated autoimmune chronic active hepatitis. *Mayo Clin Proc* 1991; **66**: 572-582 [PMID: 1646353 DOI: 10.1016/S0025-6196(12)60515-1]

137 **Lunel F**, Abuaf N, Frangeul L, Grippon P, Perrin M, Le Coz Y, Valla D, Borotto E, Yamamoto AM, Huraux JM. Liver/kidney microsome antibody type 1 and hepatitis C virus infection. *Hepatology* 1992; **16**: 630-636 [PMID: 1380479 DOI: 10.1002/hep.1840160304]

138 **Zeniya M**, Aizawa Y, Watanabe F, Kawabe T, Hara M, Sakaguchi M, Toda G. HCV-marker-positive autoimmune-type chronic active hepatitis: a possible relation between HCV infection and liver autoreaction. *Liver* 1994; **14**: 206-212 [PMID: 7526109 DOI: 10.1111/j.1600-0676.1994.tb00075.x]

139 **Savage K**, Dhillon AP, Schmilovitz-Weiss H, el-Batanony M, Brown D, Dusheiko G, Scheuer PJ. Detection of HCV-RNA in paraffin-embedded liver biopsies from patients with autoimmune hepatitis. *J Hepatol* 1995; **22**: 27-34 [PMID: 7751584 DOI: 10.1016/0168-8278(95)80256-8]

140 **Christie KE**, Haukenes G. Measles virus-specific IgM antibodies in sera from patients with chronic active hepatitis. *J Med Virol* 1983; **12**: 267-272 [PMID: 6655465 DOI: 10.1002/jmv.1890120406]

141 **Robertson DA**, Zhang SL, Guy EC, Wright R. Persistent measles virus genome in autoimmune chronic active hepatitis. *Lancet* 1987; **2**: 9-11 [PMID: 2885546 DOI: 10.1016/S0140-6736(87)93051-0]

142 **Vento S**, Cainelli F, Ferraro T, Concia E. Autoimmune hepatitis type 1 after measles. *Am J Gastroenterol* 1996; **91**: 2618-2620 [PMID: 8947001]

143 **Toyoda-Akui M**, Yokomori H, Kaneko F, Shimizu Y, Takeuchi H, Tahara K, Yoshida H, Kondo H, Motoori T, Ohbu M, Oda M, Hibi T. Association of an overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis with cytomegalovirus infection. *Int J Gen Med* 2011; **4**: 397-402 [PMID: 21731890 DOI: 10.2147/IJGM.S19245]

144 **Chiba T**, Goto S, Yokosuka O, Imazeki F, Tanaka M, Fukai K, Takahashi Y, Tsujimura H, Saisho H. Fatal chronic active Epstein-Barr virus infection mimicking autoimmune hepatitis. *Eur J Gastroenterol Hepatol* 2004; **16**: 225-228 [PMID: 15075999 DOI: 10.1097/00042737-200402000-00017]

145 **Christen U**, Hintermann E. Pathogen infection as a possible cause for autoimmune hepatitis. *Int Rev Immunol* 2014; **33**: 296-313 [PMID: 24911790 DOI: 10.3109/08830185.2014.921162]

146 **Christen U**, Hintermann E. Pathogens and autoimmune hepatitis. *Clin Exp Immunol* 2019; **195**: 35-51 [PMID: 30113082 DOI: 10.1111/cei.13203]

147 **Czaja AJ**, Carpenter HA, Santrach PJ, Moore SB, Taswell HF, Homburger HA. Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. *J Hepatol* 1993; **18**: 342-352 [PMID: 8228128 DOI: 10.1016/S0168-8278(05)80279-X]

148 **Czaja AJ**, Magrin S, Fabiano C, Fiorentino G, Diquattro O, Craxi A, Pagliaro L. Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. *Dig Dis Sci* 1995; **40**: 33-40 [PMID: 7529673 DOI: 10.1007/BF02063938]

149 **McFarlane IG**, Smith HM, Johnson PJ, Bray GP, Vergani D, Williams R. Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? *Lancet* 1990; **335**: 754-757 [PMID: 1969512 DOI: 10.1016/0140-6736(90)90870-B]

150 **Czaja AJ**, Taswell HF, Rakela J, Rabe D. Duration and specificity of antibodies to hepatitis C virus in chronic active hepatitis. *Gastroenterology* 1992; **102**: 1675-1679 [PMID: 1314751 DOI: 10.1016/0016-5085(92)91729-N]

151 **Czaja AJ**, Abdulkarim AS, Carpenter HA, Perez RG, Persing DH, Zein NN. GB virus-C infection in type 1 autoimmune hepatitis. *Mayo Clin Proc* 1998; **73**: 412-418 [PMID: 9581580 DOI: 10.4065/73.5.412]

152 **Charlton M**, Adjei P, Poterucha J, Zein N, Moore B, Therneau T, Krom R, Wiesner R. TT-virus infection in North American blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis. *Hepatology* 1998; **28**: 839-842 [PMID: 9731581 DOI: 10.1002/hep.510280335]

153 **Fainboim L**, Cañero Velasco MC, Marcos CY, Ciocca M, Roy A, Theiler G, Capucchio M, Nuncifora S, Sala L, Zelazko M. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB\*1301, a marker for pediatric autoimmune hepatitis. *Hepatology* 2001; **33**: 1512-1517 [PMID: 11391541 DOI: 10.1053/jhep.2001.24562]

154 **Christen U**, von Herrath MG. Do viral infections protect from or enhance type 1 diabetes and how can we tell the difference? *Cell Mol Immunol* 2011; **8**: 193-198 [PMID: 21258361 DOI: 10.1038/cmi.2010.71]

155 **Albert LJ**, Inman RD. Molecular mimicry and autoimmunity. *N Engl J Med* 1999; **341**: 2068-2074 [PMID: 10615080 DOI: 10.1056/NEJM199912303412707]

156 **Oldstone MB**. Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept. *Curr Top Microbiol Immunol* 2005; **296**: 1-17 [PMID: 16329189 DOI: 10.1007/3-540-30791-5\_1]

157 **Scherer MT**, Ignatowicz L, Winslow GM, Kappler JW, Marrack P. Superantigens: bacterial and viral proteins that manipulate the immune system. *Annu Rev Cell Biol* 1993; **9**: 101-128 [PMID: 7506550 DOI: 10.1146/annurev.cb.09.110193.000533]

158 **Llewelyn M**, Cohen J. Superantigens: microbial agents that corrupt immunity. *Lancet Infect Dis* 2002; **2**: 156-162 [PMID: 11944185 DOI: 10.1016/S1473-3099(02)00222-0]

159 **Schiffenbauer J**. Superantigens and their role in autoimmune disorders. *Arch Immunol Ther Exp (Warsz)* 1999; **47**: 17-24 [PMID: 11729824]

160 **Marrack P**, Kappler J. The staphylococcal enterotoxins and their relatives. *Science* 1990; **248**: 705-711 [PMID: 2185544 DOI: 10.1126/science.2185544]

161 **Li H**, Llera A, Malchiodi EL, Mariuzza RA. The structural basis of T cell activation by superantigens. *Annu Rev Immunol* 1999; **17**: 435-466 [PMID: 10358765 DOI: 10.1146/annurev.immunol.17.1.435]

162 **Miethke T**, Wahl C, Heeg K, Echtenacher B, Krammer PH, Wagner H. T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. *J Exp Med* 1992; **175**: 91-98 [PMID: 1730929 DOI: 10.1084/jem.175.1.91]

163 **Norrby-Teglund A**, Norgren M, Holm SE, Andersson U, Andersson J. Similar cytokine induction profiles of a novel streptococcal exotoxin, MF, and pyrogenic exotoxins A and B. *Infect Immun* 1994; **62**: 3731-3738 [PMID: 8063387]

164 **Choi Y**, Lafferty JA, Clements JR, Todd JK, Gelfand EW, Kappler J, Marrack P, Kotzin BL. Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. *J Exp Med* 1990; **172**: 981-984 [PMID: 2117641 DOI: 10.1084/jem.172.3.981]

165 **Schiffenbauer J**, Johnson HM, Butfiloski EJ, Wegrzyn L, Soos JM. Staphylococcal enterotoxins can reactivate experimental allergic encephalomyelitis. *Proc Natl Acad Sci U S A* 1993; **90**: 8543-8546 [PMID: 8378329 DOI: 10.1073/pnas.90.18.8543]

166 **Paliard X**, West SG, Lafferty JA, Clements JR, Kappler JW, Marrack P, Kotzin BL. Evidence for the effects of a superantigen in rheumatoid arthritis. *Science* 1991; **253**: 325-329 [PMID: 1857971 DOI: 10.1126/science.1857971]

167 **Howell MD**, Diveley JP, Lundeen KA, Esty A, Winters ST, Carlo DJ, Brostoff SW. Limited T-cell receptor beta-chain heterogeneity among interleukin 2 receptor-positive synovial T cells suggests a role for superantigen in rheumatoid arthritis. *Proc Natl Acad Sci U S A* 1991; **88**: 10921-10925 [PMID: 1660155 DOI: 10.1073/pnas.88.23.10921]

168 **Björnsson E**, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, Neuhauser M, Lindor K. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. *Hepatology* 2010; **51**: 2040-2048 [PMID: 20512992 DOI: 10.1002/hep.23588]

169 **Czaja AJ**. Drug-induced autoimmune-like hepatitis. *Dig Dis Sci* 2011; **56**: 958-976 [PMID: 21327704 DOI: 10.1007/s10620-011-1611-4]

170 **Björnsson ES**, Gunnarsson BI, Gröndal G, Jonasson JG, Einarsdottir R, Ludviksson BR, Gudbjörnsson B, Olafsson S. Risk of drug-induced liver injury from tumor necrosis factor antagonists. *Clin Gastroenterol Hepatol* 2015; **13**: 602-608 [PMID: 25131534 DOI: 10.1016/j.cgh.2014.07.062]

171 **Kamiyama T**, Nouchi T, Kojima S, Murata N, Ikeda T, Sato C. Autoimmune hepatitis triggered by administration of an herbal medicine. *Am J Gastroenterol* 1997; **92**: 703-704 [PMID: 9128330]

172 **Cohen SM**, O'Connor AM, Hart J, Merel NH, Te HS. Autoimmune hepatitis associated with the use of black cohosh: a case study. *Menopause* 2004; **11**: 575-577 [PMID: 15356412 DOI: 10.1097/01.gme.0000142914.55849.6a]

173 **Guzman G**, Kallwitz ER, Wojewoda C, Chennuri R, Berkes J, Layden TJ, Cotler SJ. Liver Injury with Features Mimicking Autoimmune Hepatitis following the Use of Black Cohosh. *Case Rep Med* 2009; **2009**: 918156 [PMID: 20130783 DOI: 10.1155/2009/918156]

174 **Borum ML**. Fulminant exacerbation of autoimmune hepatitis after the use of ma huang. *Am J Gastroenterol* 2001; **96**: 1654-1655 [PMID: 11374728 DOI: 10.1111/j.1572-0241.2001.03827.x]

175 **Gilbert KM**, Przybyla B, Pumford NR, Han T, Fuscoe J, Schnackenberg LK, Holland RD, Doss JC, Macmillan-Crow LA, Blossom SJ. Delineating liver events in trichloroethylene-induced autoimmune hepatitis. *Chem Res Toxicol* 2009; **22**: 626-632 [PMID: 19254012 DOI: 10.1021/tx800409r]

176 **Pohl LR**, Kenna JG, Satoh H, Christ D, Martin JL. Neoantigens associated with halothane hepatitis. *Drug Metab Rev* 1989; **20**: 203-217 [PMID: 2680380 DOI: 10.3109/03602538909103537]

177 **Zimmerman HJ**. Drug-induced liver disease. *Clin Liver Dis* 2000; **4**: 73-96, vi [PMID: 11232192 DOI: 10.1016/S1089-3261(05)70097-0]

178 **Robin MA**, Le Roy M, Descatoire V, Pessayre D. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. *J Hepatol* 1997; **26**: 23-30 [PMID: 9138125 DOI: 10.1016/S0168-8278(97)82329-X]

179 **Eliasson E**, Gardner I, Hume-Smith H, de Waziers I, Beaune P, Kenna JG. Interindividual variability in P450-dependent generation of neoantigens in halothane hepatitis. *Chem Biol Interact* 1998; **116**: 123-141 [PMID: 9877205 DOI: 10.1016/S0009-2797(98)00081-7]

180 **Hokland P**, Hokland M, Cotter F. The Nobel Prize for Medicine awarded for cancer therapy by inhibition of negative immune regulation. *Br J Haematol* 2018; **183**: 698-700 [PMID: 30488426 DOI: 10.1111/bjh.15694]

181 **Wei SC**, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. *Cancer Discov* 2018; **8**: 1069-1086 [PMID: 30115704 DOI: 10.1158/2159-8290.CD-18-0367]

182 **Peggs KS**, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. *J Exp Med* 2009; **206**: 1717-1725 [PMID: 19581407 DOI: 10.1084/jem.20082492]

183 **Topalian SL**, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. *Curr Opin Immunol* 2012; **24**: 207-212 [PMID: 22236695 DOI: 10.1016/j.coi.2011.12.009]

184 **Quezada SA**, Peggs KS. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. *Br J Cancer* 2013; **108**: 1560-1565 [PMID: 23511566 DOI: 10.1038/bjc.2013.117]

185 **Riaz N**, Morris L, Havel JJ, Makarov V, Desrichard A, Chan TA. The role of neoantigens in response to immune checkpoint blockade. *Int Immunol* 2016; **28**: 411-419 [PMID: 27048318 DOI: 10.1093/intimm/dxw019]

186 **Tocut M**, Brenner R, Zandman-Goddard G. Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. *Autoimmun Rev* 2018; **17**: 610-616 [PMID: 29631064 DOI: 10.1016/j.autrev.2018.01.010]

187 **King GT**, Sharma P, Davis SL, Jimeno A. Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy. *Drugs Today (Barc)* 2018; **54**: 103-122 [PMID: 29637937 DOI: 10.1358/dot.2018.54.2.2776626]

188 **Akturk HK**, Alkanani A, Zhao Z, Yu L, Michels AW. PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity. *J Clin Endocrinol Metab* 2018; **103**: 3589-3592 [PMID: 30124874 DOI: 10.1210/jc.2018-01430]

189 **Parakh S**, Cebon J, Klein O. Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy. *Oncologist* 2018; **23**: 849-851 [PMID: 29666298 DOI: 10.1634/theoncologist.2017-0531]

190 **Suzman DL**, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents. *Liver Int* 2018; **38**: 976-987 [PMID: 29603856 DOI: 10.1111/liv.13746]

191 **Zen Y**, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. *Mod Pathol* 2018; **31**: 965-973 [PMID: 29403081 DOI: 10.1038/s41379-018-0013-y]

192 **De Martin E**, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, Robert C, Marabelle A, Guettier C, Samuel D. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. *J Hepatol* 2018; **68**: 1181-1190 [PMID: 29427729 DOI: 10.1016/j.jhep.2018.01.033]

193 **Jennings JJ**, Mandaliya R, Nakshabandi A, Lewis JH. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. *Expert Opin Drug Metab Toxicol* 2019; **15**: 231-244 [PMID: 30677306 DOI: 10.1080/17425255.2019.1574744]

194 **Nishida N**, Kudo M. Liver damage related to immune checkpoint inhibitors. *Hepatol Int* 2019; **13**: 248-252 [PMID: 30607787 DOI: 10.1007/s12072-018-9921-7]

195 **Reddy HG**, Schneider BJ, Tai AW. Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis. *Clin Transl Gastroenterol* 2018; **9**: 180 [PMID: 30228268 DOI: 10.1038/s41424-018-0049-9]

196 **Kim KW**, Ramaiya NH, Krajewski KM, Jagannathan JP, Tirumani SH, Srivastava A, Ibrahim N. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. *Invest New Drugs* 2013; **31**: 1071-1077 [PMID: 23408334 DOI: 10.1007/s10637-013-9939-6]

197 **Johncilla M**, Misdraji J, Pratt DS, Agoston AT, Lauwers GY, Srivastava A, Doyle LA. Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases. *Am J Surg Pathol* 2015; **39**: 1075-1084 [PMID: 26034866 DOI: 10.1097/PAS.0000000000000453]

198 **Doherty GJ**, Duckworth AM, Davies SE, Mells GF, Brais R, Harden SV, Parkinson CA, Corrie PG. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. *ESMO Open* 2017; **2**: e000268 [PMID: 29081991 DOI: 10.1136/esmoopen-2017-000268]

199 **Richardson B**. Effect of an inhibitor of DNA methylation on T cells. II. 5-Azacytidine induces self-reactivity in antigen-specific T4+ cells. *Hum Immunol* 1986; **17**: 456-470 [PMID: 2432050 DOI: 10.1016/0198-8859(86)90304-6]

200 **Cornacchia E**, Golbus J, Maybaum J, Strahler J, Hanash S, Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. *J Immunol* 1988; **140**: 2197-2200 [PMID: 3258330]

201 **Scheinbart LS**, Johnson MA, Gross LA, Edelstein SR, Richardson BC. Procainamide inhibits DNA methyltransferase in a human T cell line. *J Rheumatol* 1991; **18**: 530-534 [PMID: 2066944]

202 **Quddus J**, Johnson KJ, Gavalchin J, Amento EP, Chrisp CE, Yung RL, Richardson BC. Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. *J Clin Invest* 1993; **92**: 38-53 [PMID: 7686923 DOI: 10.1172/JCI116576]

203 **Christman JK**. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. *Oncogene* 2002; **21**: 5483-5495 [PMID: 12154409 DOI: 10.1038/sj.onc.1205699]

204 **Issa JP**. Aging and epigenetic drift: a vicious cycle. *J Clin Invest* 2014; **124**: 24-29 [PMID: 24382386 DOI: 10.1172/JCI69735]

205 **Maegawa S**, Gough SM, Watanabe-Okochi N, Lu Y, Zhang N, Castoro RJ, Estecio MR, Jelinek J, Liang S, Kitamura T, Aplan PD, Issa JP. Age-related epigenetic drift in the pathogenesis of MDS and AML. *Genome Res* 2014; **24**: 580-591 [PMID: 24414704 DOI: 10.1101/gr.157529.113]

206 **Dozmorov MG**, Coit P, Maksimowicz-McKinnon K, Sawalha AH. Age-associated DNA methylation changes in naive CD4+ T cells suggest an evolving autoimmune epigenotype in aging T cells. *Epigenomics* 2017; **9**: 429-445 [PMID: 28322571 DOI: 10.2217/epi-2016-0143]

207 **Somers EC**, Richardson BC. Environmental exposures, epigenetic changes and the risk of lupus. *Lupus* 2014; **23**: 568-576 [PMID: 24763540 DOI: 10.1177/0961203313499419]

208 **Cañas CA**, Cañas F, Bonilla-Abadía F, Ospina FE, Tobón GJ. Epigenetics changes associated to environmental triggers in autoimmunity. *Autoimmunity* 2016; **49**: 1-11 [PMID: 26369426 DOI: 10.3109/08916934.2015.1086996]

209 **Efe C**, Kav T, Aydin C, Cengiz M, Imga NN, Purnak T, Smyk DS, Torgutalp M, Turhan T, Ozenirler S, Ozaslan E, Bogdanos DP. Low serum vitamin D levels are associated with severe histological features and poor response to therapy in patients with autoimmune hepatitis. *Dig Dis Sci* 2014; **59**: 3035-3042 [PMID: 25002309 DOI: 10.1007/s10620-014-3267-3]

210 **Ebadi M**, Bhanji RA, Mazurak VC, Lytvyak E, Mason A, Czaja AJ, Montano-Loza AJ. Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis. *Aliment Pharmacol Ther* 2019; **49**: 173-182 [PMID: 30484857 DOI: 10.1111/apt.15029]

211 **Czaja AJ**, Montano-Loza AJ. Evolving Role of Vitamin D in Immune-Mediated Disease and Its Implications in Autoimmune Hepatitis. *Dig Dis Sci* 2019; **64**: 324-344 [PMID: 30370494 DOI: 10.1007/s10620-018-5351-6]

212 **Vogel A**, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. *Hepatology* 2002; **35**: 126-131 [PMID: 11786968 DOI: 10.1053/jhep.2002.30084]

213 **Fan L**, Tu X, Zhu Y, Zhou L, Pfeiffer T, Feltens R, Stoecker W, Zhong R. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. *J Gastroenterol Hepatol* 2005; **20**: 249-255 [PMID: 15683428 DOI: 10.1111/j.1440-1746.2005.03532.x]

214 **Christen U**, Hintermann E, Holdener M, von Herrath MG. Viral triggers for autoimmunity: is the 'glass of molecular mimicry' half full or half empty? *J Autoimmun* 2010; **34**: 38-44 [PMID: 19716269 DOI: 10.1016/j.jaut.2009.08.001]

215 **Alam J**, Kim YC, Choi Y. Potential role of bacterial infection in autoimmune diseases: a new aspect of molecular mimicry. *Immune Netw* 2014; **14**: 7-13 [PMID: 24605075 DOI: 10.4110/in.2014.14.1.7]

216 **Fujinami RS**, Oldstone MB, Wroblewska Z, Frankel ME, Koprowski H. Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. *Proc Natl Acad Sci USA* 1983; **80**: 2346-2350 [PMID: 6300911 DOI: 10.1073/pnas.80.8.2346]

217 **Fujinami RS**, Oldstone MB. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. *Science* 1985; **230**: 1043-1045 [PMID: 2414848 DOI: 10.1126/science.2414848]

218 **Wucherpfennig KW**. Mechanisms for the induction of autoimmunity by infectious agents. *J Clin Invest* 2001; **108**: 1097-1104 [PMID: 11602615 DOI: 10.1172/JCI14235]

219 **Gut J**, Christen U, Huwyler J. Mechanisms of halothane toxicity: novel insights. *Pharmacol Ther* 1993; **58**: 133-155 [PMID: 8415876 DOI: 10.1016/0163-7258(93)90047-H]

220 **Christen U**, Quinn J, Yeaman SJ, Kenna JG, Clarke JB, Gandolfi AJ, Gut J. Identification of the dihydrolipoamide acetyltransferase subunit of the human pyruvate dehydrogenase complex as an autoantigen in halothane hepatitis. Molecular mimicry of trifluoroacetyl-lysine by lipoic acid. *Eur J Biochem* 1994; **223**: 1035-1047 [PMID: 7519986 DOI: 10.1111/j.1432-1033.1994.tb19082.x]

221 **Long SA**, Quan C, Van de Water J, Nantz MH, Kurth MJ, Barsky D, Colvin ME, Lam KS, Coppel RL, Ansari A, Gershwin ME. Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis. *J Immunol* 2001; **167**: 2956-2963 [PMID: 11509645 DOI: 10.4049/jimmunol.167.5.2956]

222 **Wakabayashi K**, Lian ZX, Leung PS, Moritoki Y, Tsuneyama K, Kurth MJ, Lam KS, Yoshida K, Yang GX, Hibi T, Ansari AA, Ridgway WM, Coppel RL, Mackay IR, Gershwin ME. Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. *Hepatology* 2008; **48**: 531-540 [PMID: 18563844 DOI: 10.1002/hep.22390]

223 **Wakabayashi K**, Yoshida K, Leung PS, Moritoki Y, Yang GX, Tsuneyama K, Lian ZX, Hibi T, Ansari AA, Wicker LS, Ridgway WM, Coppel RL, Mackay IR, Gershwin ME. Induction of autoimmune cholangitis in non-obese diabetic (NOD).1101 mice following a chemical xenobiotic immunization. *Clin Exp Immunol* 2009; **155**: 577-586 [PMID: 19094117 DOI: 10.1111/j.1365-2249.2008.03837.x]

224 **Agmon-Levin N**, Paz Z, Israeli E, Shoenfeld Y. Vaccines and autoimmunity. *Nat Rev Rheumatol* 2009; **5**: 648-652 [PMID: 19865091 DOI: 10.1038/nrrheum.2009.196]

225 **Kanduc D**. Peptide cross-reactivity: the original sin of vaccines. *Front Biosci (Schol Ed)* 2012; **4**: 1393-1401 [PMID: 22652881 DOI: 10.2741/s341]

226 **Ehser J**, Holdener M, Christen S, Bayer M, Pfeilschifter JM, Hintermann E, Bogdanos D, Christen U. Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis. *J Autoimmun* 2013; **42**: 39-49 [PMID: 23200317 DOI: 10.1016/j.jaut.2012.11.001]

227 **Damian RT**. Molecular Mimicry in Biological Adaptation. *Science* 1965; **147**: 824 [PMID: 17793550 DOI: 10.1126/science.147.3660.824-b]

228 **Pahari S**, Chatterjee D, Negi S, Kaur J, Singh B, Agrewala JN. Morbid Sequences Suggest Molecular Mimicry between Microbial Peptides and Self-Antigens: A Possibility of Inciting Autoimmunity. *Front Microbiol* 2017; **8**: 1938 [PMID: 29062305 DOI: 10.3389/fmicb.2017.01938]

229 **Krisher K**, Cunningham MW. Myosin: a link between streptococci and heart. *Science* 1985; **227**: 413-415 [PMID: 2578225 DOI: 10.1126/science.2578225]

230 **Ellis NM**, Li Y, Hildebrand W, Fischetti VA, Cunningham MW. T cell mimicry and epitope specificity of cross-reactive T cell clones from rheumatic heart disease. *J Immunol* 2005; **175**: 5448-5456 [PMID: 16210652 DOI: 10.4049/jimmunol.175.8.5448]

231 **Guilherme L**, Kalil J, Cunningham M. Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease. *Autoimmunity* 2006; **39**: 31-39 [PMID: 16455580 DOI: 10.1080/08916930500484674]

232 **Faé KC**, da Silva DD, Oshiro SE, Tanaka AC, Pomerantzeff PM, Douay C, Charron D, Toubert A, Cunningham MW, Kalil J, Guilherme L. Mimicry in recognition of cardiac myosin peptides by heart-intralesional T cell clones from rheumatic heart disease. *J Immunol* 2006; **176**: 5662-5670 [PMID: 16622036 DOI: 10.4049/jimmunol.176.9.5662]

233 **Cunningham MW**. Streptococcus and rheumatic fever. *Curr Opin Rheumatol* 2012; **24**: 408-416 [PMID: 22617826 DOI: 10.1097/BOR.0b013e32835461d3]

234 **Cunningham MW**. Rheumatic fever, autoimmunity, and molecular mimicry: the streptococcal connection. *Int Rev Immunol* 2014; **33**: 314-329 [PMID: 24892819 DOI: 10.3109/08830185.2014.917411]

235 **Sheikh KA**, Zhang G, Gong Y, Schnaar RL, Griffin JW. An anti-ganglioside antibody-secreting hybridoma induces neuropathy in mice. *Ann Neurol* 2004; **56**: 228-239 [PMID: 15293275 DOI: 10.1002/ana.20173]

236 **Ang CW**, Jacobs BC, Laman JD. The Guillain-Barré syndrome: a true case of molecular mimicry. *Trends Immunol* 2004; **25**: 61-66 [PMID: 15102364 DOI: 10.1016/j.it.2003.12.004]

237 **Gross DM**, Forsthuber T, Tary-Lehmann M, Etling C, Ito K, Nagy ZA, Field JA, Steere AC, Huber BT. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. *Science* 1998; **281**: 703-706 [PMID: 9685265 DOI: 10.1126/science.281.5377.703]

238 **Benoist C**, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? *Nat Immunol* 2001; **2**: 797-801 [PMID: 11526389 DOI: 10.1038/ni0901-797]

239 **Schwimmbeck PL**, Yu DT, Oldstone MB. Autoantibodies to HLA B27 in the sera of HLA B27 patients with ankylosing spondylitis and Reiter's syndrome. Molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease. *J Exp Med* 1987; **166**: 173-181 [PMID: 2439632 DOI: 10.1084/jem.166.1.173]

240 **Schwimmbeck PL**, Oldstone MB. Klebsiella pneumoniae and HLA B27-associated diseases of Reiter's syndrome and ankylosing spondylitis. *Curr Top Microbiol Immunol* 1989; **145**: 45-56 [PMID: 2680296 DOI: 10.1007/978-3-642-74594-2\_4]

241 **Fielder M**, Pirt SJ, Tarpey I, Wilson C, Cunningham P, Ettelaie C, Binder A, Bansal S, Ebringer A. Molecular mimicry and ankylosing spondylitis: possible role of a novel sequence in pullulanase of Klebsiella pneumoniae. *FEBS Lett* 1995; **369**: 243-248 [PMID: 7649265 DOI: 10.1016/0014-5793(95)00760-7]

242 **Albani S**, Keystone EC, Nelson JL, Ollier WE, La Cava A, Montemayor AC, Weber DA, Montecucco C, Martini A, Carson DA. Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. *Nat Med* 1995; **1**: 448-452 [PMID: 7585093 DOI: 10.1038/nm0595-448]

243 **McClain MT**, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. *Nat Med* 2005; **11**: 85-89 [PMID: 15619631 DOI: 10.1038/nm1167]

244 **Manns MP**, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. *J Clin Invest* 1991; **88**: 1370-1378 [PMID: 1717511 DOI: 10.1172/JCI115443]

245 **Ma Y**, Thomas MG, Okamoto M, Bogdanos DP, Nagl S, Kerkar N, Lopes AR, Muratori L, Lenzi M, Bianchi FB, Mieli-Vergani G, Vergani D. Key residues of a major cytochrome P4502D6 epitope are located on the surface of the molecule. *J Immunol* 2002; **169**: 277-285 [PMID: 12077255 DOI: 10.4049/jimmunol.169.1.277]

246 **Kerkar N**, Choudhuri K, Ma Y, Mahmoud A, Bogdanos DP, Muratori L, Bianchi F, Williams R, Mieli-Vergani G, Vergani D. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. *J Immunol* 2003; **170**: 1481-1489 [PMID: 12538711 DOI: 10.4049/jimmunol.170.3.1481]

247 **Selmi C**, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, Leung PS, Kenny TP, Van De Water J, Nantz MH, Kurth MJ, Gershwin ME. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. *Hepatology* 2003; **38**: 1250-1257 [PMID: 14578864 DOI: 10.1053/jhep.2003.50446]

248 **Olafsson S**, Gudjonsson H, Selmi C, Amano K, Invernizzi P, Podda M, Gershwin ME. Antimitochondrial antibodies and reactivity to N. aromaticivorans proteins in Icelandic patients with primary biliary cirrhosis and their relatives. *Am J Gastroenterol* 2004; **99**: 2143-2146 [PMID: 15554994 DOI: 10.1111/j.1572-0241.2004.40397.x]

249 **Bogdanos DP**, Baum H, Grasso A, Okamoto M, Butler P, Ma Y, Rigopoulou E, Montalto P, Davies ET, Burroughs AK, Vergani D. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. *J Hepatol* 2004; **40**: 31-39 [PMID: 14672611 DOI: 10.1016/S0168-8278(03)00501-4]

250 **Padgett KA**, Selmi C, Kenny TP, Leung PS, Balkwill DL, Ansari AA, Coppel RL, Gershwin ME. Phylogenetic and immunological definition of four lipoylated proteins from Novosphingobium aromaticivorans, implications for primary biliary cirrhosis. *J Autoimmun* 2005; **24**: 209-219 [PMID: 15848043 DOI: 10.1016/j.jaut.2005.01.012]

251 **Ortega-Hernandez OD**, Levin NA, Altman A, Shoenfeld Y. Infectious agents in the pathogenesis of primary biliary cirrhosis. *Dis Markers* 2010; **29**: 277-286 [PMID: 21297247 DOI: 10.3233/DMA-2010-0771]

252 **Holdener M**, Hintermann E, Bayer M, Rhode A, Rodrigo E, Hintereder G, Johnson EF, Gonzalez FJ, Pfeilschifter J, Manns MP, Herrath Mv, Christen U. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. *J Exp Med* 2008; **205**: 1409-1422 [PMID: 18474629 DOI: 10.1084/jem.20071859]

253 **Trost B**, Lucchese G, Stufano A, Bickis M, Kusalik A, Kanduc D. No human protein is exempt from bacterial motifs, not even one. *Self Nonself* 2010; **1**: 328-334 [PMID: 21487508 DOI: 10.4161/self.1.4.13315]

254 **Reay PA**, Kantor RM, Davis MM. Use of global amino acid replacements to define the requirements for MHC binding and T cell recognition of moth cytochrome c (93-103). *J Immunol* 1994; **152**: 3946-3957 [PMID: 7511662]

255 **Sinigaglia F**, Hammer J. Defining rules for the peptide-MHC class II interaction. *Curr Opin Immunol* 1994; **6**: 52-56 [PMID: 7513526 DOI: 10.1016/0952-7915(94)90033-7]

256 **Sinigaglia F**, Hammer J. Rules for peptide binding to MHC class II molecules. *APMIS* 1994; **102**: 241-248 [PMID: 7516671 DOI: 10.1111/j.1699-0463.1994.tb04871.x]

257 **Wucherpfennig KW**, Sette A, Southwood S, Oseroff C, Matsui M, Strominger JL, Hafler DA. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. *J Exp Med* 1994; **179**: 279-290 [PMID: 7505801 DOI: 10.1084/jem.179.1.279]

258 **Amano K**, Leung PS, Rieger R, Quan C, Wang X, Marik J, Suen YF, Kurth MJ, Nantz MH, Ansari AA, Lam KS, Zeniya M, Matsuura E, Coppel RL, Gershwin ME. Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. *J Immunol* 2005; **174**: 5874-5883 [PMID: 15845458 DOI: 10.4049/jimmunol.174.9.5874]

259 **Rieger R**, Leung PS, Jeddeloh MR, Kurth MJ, Nantz MH, Lam KS, Barsky D, Ansari AA, Coppel RL, Mackay IR, Gershwin ME. Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. *J Autoimmun* 2006; **27**: 7-16 [PMID: 16876981 DOI: 10.1016/j.jaut.2006.06.002]

260 **Gelpi C**, Sontheimer EJ, Rodriguez-Sanchez JL. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. *Proc Natl Acad Sci U S A* 1992; **89**: 9739-9743 [PMID: 1409691 DOI: 10.1073/pnas.89.20.9739]

261 **Costa M**, Rodríguez-Sánchez JL, Czaja AJ, Gelpí C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis. *Clin Exp Immunol* 2000; **121**: 364-374 [PMID: 10931155 DOI: 10.1046/j.1365-2249.2000.01280.x]

262 **Wies I**, Brunner S, Henninger J, Herkel J, Kanzler S, Meyer zum Büschenfelde KH, Lohse AW. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. *Lancet* 2000; **355**: 1510-1515 [PMID: 10801173 DOI: 10.1016/S0140-6736(00)02166-8]

263 **Volkmann M**, Luithle D, Zentgraf H, Schnölzer M, Fiedler S, Heid H, Schulze-Bergkamen A, Strassburg CP, Gehrke SG, Manns MP. SLA/LP/tRNP((Ser)Sec) antigen in autoimmune hepatitis: identification of the native protein in human hepatic cell extract. *J Autoimmun* 2010; **34**: 59-65 [PMID: 19683415 DOI: 10.1016/j.jaut.2009.07.005]

264 **McRae BL**, Vanderlugt CL, Dal Canto MC, Miller SD. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. *J Exp Med* 1995; **182**: 75-85 [PMID: 7540658 DOI: 10.1084/jem.182.1.75]

265 **Vanderlugt CL**, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. *Nat Rev Immunol* 2002; **2**: 85-95 [PMID: 11910899 DOI: 10.1038/nri724]

266 **Deshmukh US**, Bagavant H, Lewis J, Gaskin F, Fu SM. Epitope spreading within lupus-associated ribonucleoprotein antigens. *Clin Immunol* 2005; **117**: 112-120 [PMID: 16095971 DOI: 10.1016/j.clim.2005.07.002]

267 **Horwitz MS**, Bradley LM, Harbertson J, Krahl T, Lee J, Sarvetnick N. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. *Nat Med* 1998; **4**: 781-785 [PMID: 9662368 DOI: 10.1038/nm0798-781]

268 **Lehmann PV**, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. *Nature* 1992; **358**: 155-157 [PMID: 1377368 DOI: 10.1038/358155a0]

269 **Christen U**, Hintermann E. Autoantibodies in Autoimmune Hepatitis: Can Epitopes Tell Us about the Etiology of the Disease? *Front Immunol* 2018; **9**: 163 [PMID: 29503645 DOI: 10.3389/fimmu.2018.00163]

270 **Ma WT**, Chang C, Gershwin ME, Lian ZX. Development of autoantibodies precedes clinical manifestations of autoimmune diseases: A comprehensive review. *J Autoimmun* 2017; **83**: 95-112 [PMID: 28739356 DOI: 10.1016/j.jaut.2017.07.003]

271 **Rammensee HG**. Chemistry of peptides associated with MHC class I and class II molecules. *Curr Opin Immunol* 1995; **7**: 85-96 [PMID: 7772286 DOI: 10.1016/0952-7915(95)80033-6]

272 **Li Z**, Woo CJ, Iglesias-Ussel MD, Ronai D, Scharff MD. The generation of antibody diversity through somatic hypermutation and class switch recombination. *Genes Dev* 2004; **18**: 1-11 [PMID: 14724175 DOI: 10.1101/gad.1161904]

273 **Di Noia JM**, Neuberger MS. Molecular mechanisms of antibody somatic hypermutation. *Annu Rev Biochem* 2007; **76**: 1-22 [PMID: 17328676 DOI: 10.1146/annurev.biochem.76.061705.090740]

274 **Fujinami RS**, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. *Clin Microbiol Rev* 2006; **19**: 80-94 [PMID: 16418524 DOI: 10.1128/CMR.19.1.80-94.2006]

275 **Tough DF**, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. *Science* 1996; **272**: 1947-1950 [PMID: 8658169 DOI: 10.1126/science.272.5270.1947]

276 **Tough DF**, Sun S, Sprent J. T cell stimulation in vivo by lipopolysaccharide (LPS). *J Exp Med* 1997; **185**: 2089-2094 [PMID: 9182680 DOI: 10.1084/jem.185.12.2089]

277 **Di Genova G**, Roddick J, McNicholl F, Stevenson FK. Vaccination of human subjects expands both specific and bystander memory T cells but antibody production remains vaccine specific. *Blood* 2006; **107**: 2806-2813 [PMID: 16339400 DOI: 10.1182/blood-2005-08-3255]

278 **Di Genova G**, Savelyeva N, Suchacki A, Thirdborough SM, Stevenson FK. Bystander stimulation of activated CD4+ T cells of unrelated specificity following a booster vaccination with tetanus toxoid. *Eur J Immunol* 2010; **40**: 976-985 [PMID: 20104490 DOI: 10.1002/eji.200940017]

279 **Boyman O**. Bystander activation of CD4+ T cells. *Eur J Immunol* 2010; **40**: 936-939 [PMID: 20309907 DOI: 10.1002/eji.201040466]

280 **Eberl G**, Brawand P, MacDonald HR. Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NK T or T cell activation. *J Immunol* 2000; **165**: 4305-4311 [PMID: 11035065 DOI: 10.4049/jimmunol.165.8.4305]

281 **Duke RC**. Self recognition by T cells. I. Bystander killing of target cells bearing syngeneic MHC antigens. *J Exp Med* 1989; **170**: 59-71 [PMID: 2787386 DOI: 10.1084/jem.170.1.59]

282 **Smyth MJ**, Sedgwick JD. Delayed kinetics of tumor necrosis factor-mediated bystander lysis by peptide-specific CD8+ cytotoxic T lymphocytes. *Eur J Immunol* 1998; **28**: 4162-4169 [PMID: 9862352 DOI: 10.1002/(SICI)1521-4141(199812)28:12<4162::AID-IMMU4162>3.3.CO;2-5]

283 **Nakamoto N**, Kanai T. Role of toll-like receptors in immune activation and tolerance in the liver. *Front Immunol* 2014; **5**: 221 [PMID: 24904576 DOI: 10.3389/fimmu.2014.00221]

284 **Nikolich-Zugich J**, Slifka MK, Messaoudi I. The many important facets of T-cell repertoire diversity. *Nat Rev Immunol* 2004; **4**: 123-132 [PMID: 15040585 DOI: 10.1038/nri1292]

285 **Warren RL**, Freeman JD, Zeng T, Choe G, Munro S, Moore R, Webb JR, Holt RA. Exhaustive T-cell repertoire sequencing of human peripheral blood samples reveals signatures of antigen selection and a directly measured repertoire size of at least 1 million clonotypes. *Genome Res* 2011; **21**: 790-797 [PMID: 21349924 DOI: 10.1101/gr.115428.110]

286 **Harbige J**, Eichmann M, Peakman M. New insights into non-conventional epitopes as T cell targets: The missing link for breaking immune tolerance in autoimmune disease? *J Autoimmun* 2017; **84**: 12-20 [PMID: 28803690 DOI: 10.1016/j.jaut.2017.08.001]

287 **Libbey JE**, Cusick MF, Tsunoda I, Fujinami RS. Antiviral CD8⁺ T cells cause an experimental autoimmune encephalomyelitis-like disease in naive mice. *J Neurovirol* 2012; **18**: 45-54 [PMID: 22281874 DOI: 10.1007/s13365-012-0077-2]

288 **Cusick MF**, Libbey JE, Fujinami RS. Multiple sclerosis: autoimmunity and viruses. *Curr Opin Rheumatol* 2013; **25**: 496-501 [PMID: 23656710 DOI: 10.1097/BOR.0b013e328362004d]

289 **Padovan E**, Giachino C, Cella M, Valitutti S, Acuto O, Lanzavecchia A. Normal T lymphocytes can express two different T cell receptor beta chains: implications for the mechanism of allelic exclusion. *J Exp Med* 1995; **181**: 1587-1591 [PMID: 7699339 DOI: 10.1084/jem.181.4.1587]

290 **Sarukhan A**, Garcia C, Lanoue A, von Boehmer H. Allelic inclusion of T cell receptor alpha genes poses an autoimmune hazard due to low-level expression of autospecific receptors. *Immunity* 1998; **8**: 563-570 [PMID: 9620677 DOI: 10.1016/S1074-7613(00)80561-0]

291 **Macpherson AJ**, Harris NL. Interactions between commensal intestinal bacteria and the immune system. *Nat Rev Immunol* 2004; **4**: 478-485 [PMID: 15173836 DOI: 10.1038/nri1373]

292 **Belkaid Y**, Hand TW. Role of the microbiota in immunity and inflammation. *Cell* 2014; **157**: 121-141 [PMID: 24679531 DOI: 10.1016/j.cell.2014.03.011]

293 **Geuking MB**, Köller Y, Rupp S, McCoy KD. The interplay between the gut microbiota and the immune system. *Gut Microbes* 2014; **5**: 411-418 [PMID: 24922519 DOI: 10.4161/gmic.29330]

294 **Van Praet JT**, Donovan E, Vanassche I, Drennan MB, Windels F, Dendooven A, Allais L, Cuvelier CA, van de Loo F, Norris PS, Kruglov AA, Nedospasov SA, Rabot S, Tito R, Raes J, Gaboriau-Routhiau V, Cerf-Bensussan N, Van de Wiele T, Eberl G, Ware CF, Elewaut D. Commensal microbiota influence systemic autoimmune responses. *EMBO J* 2015; **34**: 466-474 [PMID: 25599993 DOI: 10.15252/embj.201489966]

295 **Sánchez B**, Hevia A, González S, Margolles A. Interaction of Intestinal Microorganisms with the Human Host in the Framework of Autoimmune Diseases. *Front Immunol* 2015; **6**: 594 [PMID: 26635808 DOI: 10.3389/fimmu.2015.00594]

296 **Ignacio A**, Morales CI, Câmara NO, Almeida RR. Innate Sensing of the Gut Microbiota: Modulation of Inflammatory and Autoimmune Diseases. *Front Immunol* 2016; **7**: 54 [PMID: 26925061 DOI: 10.3389/fimmu.2016.00054]

297 **Human Microbiome Project Consortium**. Structure, function and diversity of the healthy human microbiome. *Nature* 2012; **486**: 207-214 [PMID: 22699609 DOI: 10.1038/nature11234]

298 **Yatsunenko T**, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP, Heath AC, Warner B, Reeder J, Kuczynski J, Caporaso JG, Lozupone CA, Lauber C, Clemente JC, Knights D, Knight R, Gordon JI. Human gut microbiome viewed across age and geography. *Nature* 2012; **486**: 222-227 [PMID: 22699611 DOI: 10.1038/nature11053]

299 **Wu GD**, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD, Lewis JD. Linking long-term dietary patterns with gut microbial enterotypes. *Science* 2011; **334**: 105-108 [PMID: 21885731 DOI: 10.1126/science.1208344]

300 **Markle JG**, Frank DN, Mortin-Toth S, Robertson CE, Feazel LM, Rolle-Kampczyk U, von Bergen M, McCoy KD, Macpherson AJ, Danska JS. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. *Science* 2013; **339**: 1084-1088 [PMID: 23328391 DOI: 10.1126/science.1233521]

301 **Miyake Y**, Yamamoto K. Role of gut microbiota in liver diseases. *Hepatol Res* 2013; **43**: 139-146 [PMID: 22970713 DOI: 10.1111/j.1872-034X.2012.01088.x]

302 **Henao-Mejia J**, Elinav E, Thaiss CA, Licona-Limon P, Flavell RA. Role of the intestinal microbiome in liver disease. *J Autoimmun* 2013; **46**: 66-73 [PMID: 24075647 DOI: 10.1016/j.jaut.2013.07.001]

303 **Rogier R**, Koenders MI, Abdollahi-Roodsaz S. Toll-like receptor mediated modulation of T cell response by commensal intestinal microbiota as a trigger for autoimmune arthritis. *J Immunol Res* 2015; **2015**: 527696 [PMID: 25802876 DOI: 10.1155/2015/527696]

304 **Watanabe A**, Sohail MA, Gomes DA, Hashmi A, Nagata J, Sutterwala FS, Mahmood S, Jhandier MN, Shi Y, Flavell RA, Mehal WZ. Inflammasome-mediated regulation of hepatic stellate cells. *Am J Physiol Gastrointest Liver Physiol* 2009; **296**: G1248-G1257 [PMID: 19359429 DOI: 10.1152/ajpgi.90223.2008]

305 **Strowig T**, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. *Nature* 2012; **481**: 278-286 [PMID: 22258606 DOI: 10.1038/nature10759]

306 **Henao-Mejia J**, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. *Nature* 2012; **482**: 179-185 [PMID: 22297845 DOI: 10.1038/nature10809]

307 **Boaru SG**, Borkham-Kamphorst E, Tihaa L, Haas U, Weiskirchen R. Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease. *J Inflamm (Lond)* 2012; **9**: 49 [PMID: 23192004 DOI: 10.1186/1476-9255-9-49]

308 **Wu HJ**, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. *Gut Microbes* 2012; **3**: 4-14 [PMID: 22356853 DOI: 10.4161/gmic.19320]

309 **Geuking MB**, Cahenzli J, Lawson MA, Ng DC, Slack E, Hapfelmeier S, McCoy KD, Macpherson AJ. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. *Immunity* 2011; **34**: 794-806 [PMID: 21596591 DOI: 10.1016/j.immuni.2011.03.021]

310 **Hänninen A**, Salmi M, Simell O, Jalkanen S. Mucosa-associated (beta 7-integrinhigh) lymphocytes accumulate early in the pancreas of NOD mice and show aberrant recirculation behavior. *Diabetes* 1996; **45**: 1173-1180 [PMID: 8772718 DOI: 10.2337/diab.45.9.1173]

311 **Paronen J**, Klemetti P, Kantele JM, Savilahti E, Perheentupa J, Akerblom HK, Vaarala O. Glutamate decarboxylase-reactive peripheral blood lymphocytes from patients with IDDM express gut-specific homing receptor alpha4beta7-integrin. *Diabetes* 1997; **46**: 583-588 [PMID: 9075797 DOI: 10.2337/diab.46.4.583]

312 **Wen L**, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, Hu C, Wong FS, Szot GL, Bluestone JA, Gordon JI, Chervonsky AV. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. *Nature* 2008; **455**: 1109-1113 [PMID: 18806780 DOI: 10.1038/nature07336]

313 **Li Y**, Liu Y, Chu CQ. Th17 Cells in Type 1 Diabetes: Role in the Pathogenesis and Regulation by Gut Microbiome. *Mediators Inflamm* 2015; **2015**: 638470 [PMID: 26843788 DOI: 10.1155/2015/638470]

314 **Mejía-León ME**, Barca AM. Diet, Microbiota and Immune System in Type 1 Diabetes Development and Evolution. *Nutrients* 2015; **7**: 9171-9184 [PMID: 26561831 DOI: 10.3390/nu7115461]

315 **Abdollahi-Roodsaz S**, Joosten LA, Koenders MI, Devesa I, Roelofs MF, Radstake TR, Heuvelmans-Jacobs M, Akira S, Nicklin MJ, Ribeiro-Dias F, van den Berg WB. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. *J Clin Invest* 2008; **118**: 205-216 [PMID: 18060042 DOI: 10.1172/JCI32639]

316 **Wu HJ**, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, Littman DR, Benoist C, Mathis D. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. *Immunity* 2010; **32**: 815-827 [PMID: 20620945 DOI: 10.1016/j.immuni.2010.06.001]

317 **Abdollahi-Roodsaz S**, Koenders MI, Walgreen B, Bolscher J, Helsen MM, van den Bersselaar LA, van Lent PL, van de Loo FA, van den Berg WB. Toll-like receptor 2 controls acute immune complex-driven arthritis in mice by regulating the inhibitory Fcγ receptor IIB. *Arthritis Rheum* 2013; **65**: 2583-2593 [PMID: 23860661 DOI: 10.1002/art.38087]

318 **Miyake S**, Kim S, Suda W, Oshima K, Nakamura M, Matsuoka T, Chihara N, Tomita A, Sato W, Kim SW, Morita H, Hattori M, Yamamura T. Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters. *PLoS One* 2015; **10**: e0137429 [PMID: 26367776 DOI: 10.1371/journal.pone.0137429]

319 **Sokol H**, Seksik P, Rigottier-Gois L, Lay C, Lepage P, Podglajen I, Marteau P, Doré J. Specificities of the fecal microbiota in inflammatory bowel disease. *Inflamm Bowel Dis* 2006; **12**: 106-111 [PMID: 16432374 DOI: 10.1097/01.MIB.0000200323.38139.c6]

320 **Garrett WS**, Gallini CA, Yatsunenko T, Michaud M, DuBois A, Delaney ML, Punit S, Karlsson M, Bry L, Glickman JN, Gordon JI, Onderdonk AB, Glimcher LH. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. *Cell Host Microbe* 2010; **8**: 292-300 [PMID: 20833380 DOI: 10.1016/j.chom.2010.08.004]

321 **Elinav E**, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, Peaper DR, Bertin J, Eisenbarth SC, Gordon JI, Flavell RA. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. *Cell* 2011; **145**: 745-757 [PMID: 21565393 DOI: 10.1016/j.cell.2011.04.022]

322 **Hopf U**, Möller B, Stemerowicz R, Lobeck H, Rodloff A, Freudenberg M, Galanos C, Huhn D. Relation between Escherichia coli R(rough)-forms in gut, lipid A in liver, and primary biliary cirrhosis. *Lancet* 1989; **2**: 1419-1422 [PMID: 2574361 DOI: 10.1016/S0140-6736(89)92034-5]

323 **Tabibian JH**, O'Hara SP, Trussoni CE, Tietz PS, Splinter PL, Mounajjed T, Hagey LR, LaRusso NF. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. *Hepatology* 2016; **63**: 185-196 [PMID: 26044703 DOI: 10.1002/hep.27927]

324 **Mueller T**, Beutler C, Picó AH, Shibolet O, Pratt DS, Pascher A, Neuhaus P, Wiedenmann B, Berg T, Podolsky DK. Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. *Liver Int* 2011; **31**: 1574-1588 [PMID: 22093333 DOI: 10.1111/j.1478-3231.2011.02635.x]

325 **Lin R**, Zhou L, Zhang J, Wang B. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. *Int J Clin Exp Pathol* 2015; **8**: 5153-5160 [PMID: 26191211]

326 **Yuksel M**, Wang Y, Tai N, Peng J, Guo J, Beland K, Lapierre P, David C, Alvarez F, Colle I, Yan H, Mieli-Vergani G, Vergani D, Ma Y, Wen L. A novel "humanized mouse" model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. *Hepatology* 2015; **62**: 1536-1550 [PMID: 26185095 DOI: 10.1002/hep.27998]

327 **Whitacre CC**, Reingold SC, O'Looney PA. A gender gap in autoimmunity. *Science* 1999; **283**: 1277-1278 [PMID: 10084932 DOI: 10.1126/science.283.5406.1277]

328 **Young NA**, Wu LC, Burd CJ, Friedman AK, Kaffenberger BH, Rajaram MV, Schlesinger LS, James H, Shupnik MA, Jarjour WN. Estrogen modulation of endosome-associated toll-like receptor 8: an IFNα-independent mechanism of sex-bias in systemic lupus erythematosus. *Clin Immunol* 2014; **151**: 66-77 [PMID: 24525049 DOI: 10.1016/j.clim.2014.01.006]

329 **Tanaka A**, Lindor K, Ansari A, Gershwin ME. Fetal microchimerisms in the mother: immunologic implications. *Liver Transpl* 2000; **6**: 138-143 [PMID: 10719011 DOI: 10.1002/lt.500060225]

330 **Lambert NC**, Evans PC, Hashizumi TL, Maloney S, Gooley T, Furst DE, Nelson JL. Cutting edge: persistent fetal microchimerism in T lymphocytes is associated with HLA-DQA1\*0501: implications in autoimmunity. *J Immunol* 2000; **164**: 5545-5548 [PMID: 10820227 DOI: 10.4049/jimmunol.164.11.5545]

331 **Carrel L**, Willard HF. X-inactivation profile reveals extensive variability in X-linked gene expression in females. *Nature* 2005; **434**: 400-404 [PMID: 15772666 DOI: 10.1038/nature03479]

332 **Yurkovetskiy L**, Burrows M, Khan AA, Graham L, Volchkov P, Becker L, Antonopoulos D, Umesaki Y, Chervonsky AV. Gender bias in autoimmunity is influenced by microbiota. *Immunity* 2013; **39**: 400-412 [PMID: 23973225 DOI: 10.1016/j.immuni.2013.08.013]

333 **Markle JG**, Frank DN, Adeli K, von Bergen M, Danska JS. Microbiome manipulation modifies sex-specific risk for autoimmunity. *Gut Microbes* 2014; **5**: 485-493 [PMID: 25007153 DOI: 10.4161/gmic.29795]

334 **Bach JF**. The effect of infections on susceptibility to autoimmune and allergic diseases. *N Engl J Med* 2002; **347**: 911-920 [PMID: 12239261 DOI: 10.1056/NEJMra020100]

335 **Okada H**, Kuhn C, Feillet H, Bach JF. The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. *Clin Exp Immunol* 2010; **160**: 1-9 [PMID: 20415844 DOI: 10.1111/j.1365-2249.2010.04139.x]

336 **Rook GA**. Hygiene hypothesis and autoimmune diseases. *Clin Rev Allergy Immunol* 2012; **42**: 5-15 [PMID: 22090147 DOI: 10.1007/s12016-011-8285-8]

337 **Daley D**. The evolution of the hygiene hypothesis: the role of early-life exposures to viruses and microbes and their relationship to asthma and allergic diseases. *Curr Opin Allergy Clin Immunol* 2014; **14**: 390-396 [PMID: 25102107 DOI: 10.1097/ACI.0000000000000101]

338 **Pross HF**, Eidinger D. Antigenic competition: a review of nonspecific antigen-induced suppression. *Adv Immunol* 1974; **18**: 133-168 [PMID: 4597621 DOI: 10.1016/S0065-2776(08)60309-0]

339 **Liacopoulos P**, Ben-Efraim S. Antigenic competition. *Prog Allergy* 1975; **18**: 97-204 [PMID: 50601 DOI: 10.1159/000395257]

340 **Rosshart SP**, Vassallo BG, Angeletti D, Hutchinson DS, Morgan AP, Takeda K, Hickman HD, McCulloch JA, Badger JH, Ajami NJ, Trinchieri G, Pardo-Manuel de Villena F, Yewdell JW, Rehermann B. Wild Mouse Gut Microbiota Promotes Host Fitness and Improves Disease Resistance. *Cell* 2017; **171**: 1015-1028.e13 [PMID: 29056339 DOI: 10.1016/j.cell.2017.09.016]

341 **Alyanakian MA**, Grela F, Aumeunier A, Chiavaroli C, Gouarin C, Bardel E, Normier G, Chatenoud L, Thieblemont N, Bach JF. Transforming growth factor-beta and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes. *Diabetes* 2006; **55**: 179-185 [PMID: 16380491 DOI: 10.2337/diabetes.55.01.06.db05-0189]

342 **Zaccone P**, Burton O, Miller N, Jones FM, Dunne DW, Cooke A. Schistosoma mansoni egg antigens induce Treg that participate in diabetes prevention in NOD mice. *Eur J Immunol* 2009; **39**: 1098-1107 [PMID: 19291704 DOI: 10.1002/eji.200838871]

343 **Kelly TK**, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. *Nat Biotechnol* 2010; **28**: 1069-1078 [PMID: 20944599 DOI: 10.1038/nbt.1678]

344 **Detich N**, Hamm S, Just G, Knox JD, Szyf M. The methyl donor S-Adenosylmethionine inhibits active demethylation of DNA: a candidate novel mechanism for the pharmacological effects of S-Adenosylmethionine. *J Biol Chem* 2003; **278**: 20812-20820 [PMID: 12676953 DOI: 10.1074/jbc.M211813200]

345 **Campbell PM**, Bovenzi V, Szyf M. Methylated DNA-binding protein 2 antisense inhibitors suppress tumourigenesis of human cancer cell lines in vitro and in vivo. *Carcinogenesis* 2004; **25**: 499-507 [PMID: 14688029 DOI: 10.1093/carcin/bgh045]

346 **Radic M**, Muller S. Epigenetics of autoantigens: new opportunities for therapy of autoimmune diseases. *Genet Epigenet* 2013; **5**: 63-70 [PMID: 25512708 DOI: 10.4137/GEG.S12144]

347 **Hamm S**, Just G, Lacoste N, Moitessier N, Szyf M, Mamer O. On the mechanism of demethylation of 5-methylcytosine in DNA. *Bioorg Med Chem Lett* 2008; **18**: 1046-1049 [PMID: 18162397 DOI: 10.1016/j.bmcl.2007.12.027]

348 **Balada E**, Ordi-Ros J, Serrano-Acedo S, Martinez-Lostao L, Vilardell-Tarrés M. Transcript overexpression of the MBD2 and MBD4 genes in CD4+ T cells from systemic lupus erythematosus patients. *J Leukoc Biol* 2007; **81**: 1609-1616 [PMID: 17360956 DOI: 10.1189/jlb.0107064]

349 **Tabibian JH**, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, Lindor KD. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. *Aliment Pharmacol Ther* 2013; **37**: 604-612 [PMID: 23384404 DOI: 10.1111/apt.12232]

350 **Tabibian JH**, Talwalkar JA, Lindor KD. Role of the microbiota and antibiotics in primary sclerosing cholangitis. *Biomed Res Int* 2013; **2013**: 389537 [PMID: 24232746 DOI: 10.1155/2013/389537]

351 **Liberal R**, Grant CR, Longhi MS, Mieli-Vergani G, Vergani D. Regulatory T cells: Mechanisms of suppression and impairment in autoimmune liver disease. *IUBMB Life* 2015; **67**: 88-97 [PMID: 25850692 DOI: 10.1002/iub.1349]

352 **Montano-Loza AJ**, Czaja AJ. Cell mediators of autoimmune hepatitis and their therapeutic implications. *Dig Dis Sci* 2015; **60**: 1528-1542 [PMID: 25487192 DOI: 10.1007/s10620-014-3473-z]

353 **Czaja AJ**. Review article: chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets. *Aliment Pharmacol Ther* 2014; **40**: 261-279 [PMID: 24890045 DOI: 10.1111/apt.12825]

354 **Czaja AJ**. Targeting apoptosis in autoimmune hepatitis. *Dig Dis Sci* 2014; **59**: 2890-2904 [PMID: 25038736 DOI: 10.1007/s10620-014-3284-2]

355 **Longhi MS**, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. *J Hepatol* 2004; **41**: 31-37 [PMID: 15246204 DOI: 10.1016/j.jhep.2004.03.008]

356 **Longhi MS**, Hussain MJ, Mitry RR, Arora SK, Mieli-Vergani G, Vergani D, Ma Y. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. *J Immunol* 2006; **176**: 4484-4491 [PMID: 16547287 DOI: 10.4049/jimmunol.176.7.4484]

357 **Peiseler M**, Sebode M, Franke B, Wortmann F, Schwinge D, Quaas A, Baron U, Olek S, Wiegard C, Lohse AW, Weiler-Normann C, Schramm C, Herkel J. FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. *J Hepatol* 2012; **57**: 125-132 [PMID: 22425700 DOI: 10.1016/j.jhep.2012.02.029]

358 **McKinney EF**, Smith KG. T cell exhaustion and immune-mediated disease-the potential for therapeutic exhaustion. *Curr Opin Immunol* 2016; **43**: 74-80 [PMID: 27744240 DOI: 10.1016/j.coi.2016.09.005]

359 **Weiler-Normann C**, Schramm C, Quaas A, Wiegard C, Glaubke C, Pannicke N, Möller S, Lohse AW. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. *J Hepatol* 2013; **58**: 529-534 [PMID: 23178709 DOI: 10.1016/j.jhep.2012.11.010]

360 **Burak KW**, Swain MG, Santodomingo-Garzon T, Lee SS, Urbanski SJ, Aspinall AI, Coffin CS, Myers RP. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. *Can J Gastroenterol* 2013; **27**: 273-280 [PMID: 23712302 DOI: 10.1155/2013/512624]

361 **Kremer JM**, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker JC, Hagerty DT, Moreland LW. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. *N Engl J Med* 2003; **349**: 1907-1915 [PMID: 14614165 DOI: 10.1056/NEJMoa035075]

362 **Kremer JM**, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, Steinfeld S, Tindall E, Becker JC, Li T, Nuamah IF, Aranda R, Moreland LW. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. *Arthritis Rheum* 2005; **52**: 2263-2271 [PMID: 16052582 DOI: 10.1002/art.21201]

363 **Larsen CP**, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobert E, Anderson D, Cowan S, Price K, Naemura J, Emswiler J, Greene J, Turk LA, Bajorath J, Townsend R, Hagerty D, Linsley PS, Peach RJ. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. *Am J Transplant* 2005; **5**: 443-453 [PMID: 15707398 DOI: 10.1111/j.1600-6143.2005.00749.x]

364 **Rigby MR**, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. *J Clin Invest* 2015; **125**: 3285-3296 [PMID: 26193635 DOI: 10.1172/JCI81722]

365 **Czaja AJ**. Adoptive cell transfer in autoimmune hepatitis. *Expert Rev Gastroenterol Hepatol* 2015; **9**: 821-836 [PMID: 25719553 DOI: 10.1586/17474124.2015.1019470]

366 **Lapierre P**, Béland K, Yang R, Alvarez F. Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance. *Hepatology* 2013; **57**: 217-227 [PMID: 22911361 DOI: 10.1002/hep.26023]

367 **Seki T**, Ota M, Furuta S, Fukushima H, Kondo T, Hino K, Mizuki N, Ando A, Tsuji K, Inoko H. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. *Gastroenterology* 1992; **103**: 1041-1047 [PMID: 1354193 DOI: 10.1016/0016-5085(92)90041-V]

368 **Fainboim L**, Marcos Y, Pando M, Capucchio M, Reyes GB, Galoppo C, Badía I, Remondino G, Ciocca M, Ramonet M. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA-DR6 (DRB1\*1301) haplotype. *Hum Immunol* 1994; **41**: 146-150 [PMID: 7860360 DOI: 10.1016/0198-8859(94)90008-6]

369 **Djilali-Saiah I**, Fakhfakh A, Louafi H, Caillat-Zucman S, Debray D, Alvarez F. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. *J Hepatol* 2006; **45**: 844-850 [PMID: 17050030 DOI: 10.1016/j.jhep.2006.07.034]

370 **Hiraide A**, Imazeki F, Yokosuka O, Kanda T, Kojima H, Fukai K, Suzuki Y, Hata A, Saisho H. Fas polymorphisms influence susceptibility to autoimmune hepatitis. *Am J Gastroenterol* 2005; **100**: 1322-1329 [PMID: 15929764 DOI: 10.1111/j.1572-0241.2005.41053.x]

371 **Tang J**, Zhou C, Zhang ZJ, Zheng SS. Association of polymorphisms in non-classic MHC genes with susceptibility to autoimmune hepatitis. *Hepatobiliary Pancreat Dis Int* 2012; **11**: 125-131 [PMID: 22484578 DOI: 10.1016/S1499-3872(12)60136-2]

372 **Li S**, Huang X, Zhong H, Chen Z, Peng Q, Deng Y, Qin X. Tumour necrosis factor alpha (TNF-α) genetic polymorphisms and the risk of autoimmune liver disease: a meta-analysis. *J Genet* 2013; **92**: 617-628 [PMID: 24371186 DOI: 10.1007/s12041-013-0272-9]

373 **Czaja AJ**, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. *Gastroenterology* 1993; **105**: 1502-1507 [PMID: 8224654 DOI: 10.1016/0016-5085(93)90157-8]

374 **Bittencourt PL**, Goldberg AC, Cançado EL, Porta G, Carrilho FJ, Farias AQ, Palacios SA, Chiarella JM, Abrantes-Lemos CP, Baggio VL, Laudanna AA, Kalil J. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. *Am J Gastroenterol* 1999; **94**: 1906-1913 [PMID: 10406258 DOI: 10.1111/j.1572-0241.1999.01229.x]

375 **Czaja AJ**, Kruger M, Santrach PJ, Moore SB, Manns MP. Genetic distinctions between types 1 and 2 autoimmune hepatitis. *Am J Gastroenterol* 1997; **92**: 2197-2200 [PMID: 9399751]

376 **O'Hehir RE**, Lamb JR. Induction of specific clonal anergy in human T lymphocytes by Staphylococcus aureus enterotoxins. *Proc Natl Acad Sci U S A* 1990; **87**: 8884-8888 [PMID: 1978940 DOI: 10.1073/pnas.87.22.8884]

377 **Miethke T**, Wahl C, Heeg K, Wagner H. Acquired resistance to superantigen-induced T cell shock. V beta selective T cell unresponsiveness unfolds directly from a transient state of hyperreactivity. *J Immunol* 1993; **150**: 3776-3784 [PMID: 8473732]

378 **Carlberg C**. The vitamin D(3) receptor in the context of the nuclear receptor superfamily : The central role of the retinoid X receptor. *Endocrine* 1996; **4**: 91-105 [PMID: 21153264 DOI: 10.1007/BF02782754]

379 **Pike JW**, Meyer MB. The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3). *Endocrinol Metab Clin North Am* 2010; **39**: 255-269, table of contents [PMID: 20511050 DOI: 10.1016/j.ecl.2010.02.007]

380 **Lennon-Duménil AM**, Bakker AH, Wolf-Bryant P, Ploegh HL, Lagaudrière-Gesbert C. A closer look at proteolysis and MHC-class-II-restricted antigen presentation. *Curr Opin Immunol* 2002; **14**: 15-21 [PMID: 11790528 DOI: 10.1016/S0952-7915(01)00293-X]

381 **Fiebiger E**, Meraner P, Weber E, Fang IF, Stingl G, Ploegh H, Maurer D. Cytokines regulate proteolysis in major histocompatibility complex class II-dependent antigen presentation by dendritic cells. *J Exp Med* 2001; **193**: 881-892 [PMID: 11304549 DOI: 10.1084/jem.193.8.881]

**P-Reviewer:** Aguilera I, Muratori P, Rajcani J

**S-Editor:** Tang JZ **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** United States

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Factors affecting susceptibility to autoimmune hepatitis**

|  |  |  |
| --- | --- | --- |
| **Factors** | **Features** | **Pathogenic Implications in AIH** |
| Genetic predispositions | *DRB1\*03:01* and *DRB1\*04:01* in white European and North American patients[[16](#_ENREF_16),[18](#_ENREF_18),[47](#_ENREF_47)]  *DRB1\*04:04* and *DRB1\*04:05* in Asian and Mexican patients[[49](#_ENREF_49),[51](#_ENREF_51),[52](#_ENREF_52),[55](#_ENREF_55),[367](#_ENREF_367)]  *DRB1\*13:01* in South American children in and *DRB1\*04:05* in adults[[50](#_ENREF_50),[53](#_ENREF_53),[58](#_ENREF_58),[368](#_ENREF_368)]  *DQB1\*02*01, *DRB1\*07* and *DRB1\*03* in patients (mainly children) with anti-LKM1[[369](#_ENREF_369)]  Polymorphisms of *TNFα*, *Fas*, *CTLA4*, and *SH2B3* variably involved[[48](#_ENREF_48),[56](#_ENREF_56),[60-62](#_ENREF_60),[65](#_ENREF_65),[370-372](#_ENREF_370)] | *DRB1\*03:01* associated with young age, severity, cirrhosis, and poor outcome[[18](#_ENREF_18),[47](#_ENREF_47)]  *DRB1\*04:01* associated with elderly, concurrent immune diseases, treatment response[[16](#_ENREF_16),[18](#_ENREF_18),[373](#_ENREF_373)]  *DRB1\*13:01* distinguishes South American children from adults[[58](#_ENREF_58),[368](#_ENREF_368)]  *DQB1\*02:01* and *DRB1\*07* associated with type 2 (anti-LKM1-positive) AIH[[369](#_ENREF_369),[374](#_ENREF_374),[375](#_ENREF_375)]  Genetics explain 51%-55% of risk-burden[[23](#_ENREF_23),[25](#_ENREF_25),[47](#_ENREF_47),[65](#_ENREF_65)]  Polymorphisms may be discovered by GWAS[[23](#_ENREF_23)] |
| Epigenetic changes | Alter structure of nucleosomes[[25](#_ENREF_25),[26](#_ENREF_26)]  Affect transcriptional activity of genes[[67-69](#_ENREF_67)]  Responsive to environmental cues[[26](#_ENREF_26),[67](#_ENREF_67)]  Changes may be inherited[[26](#_ENREF_26),[67](#_ENREF_67)]  DNA methylation represses gene activity[[70](#_ENREF_70)]  DNA hypomethylation activates gene[[77-81](#_ENREF_77)]  Histone acetylation, phosphorylation, methylation, and ubiquitination can activate or repress gene activity[[72](#_ENREF_72),[86](#_ENREF_86),[87](#_ENREF_87),[92](#_ENREF_92)]  MiRNAs silence genes[[73](#_ENREF_73),[94-96](#_ENREF_94)] | miR-21 and miR-122 increased in AIH[[103](#_ENREF_103)]  Hypomethylation of gene promoters in SLE and PBC may promote autoimmunity[[82-85](#_ENREF_82)]  Histone acetylation can increase Tregs or expression of pro-inflammatory genes[[88](#_ENREF_88),[89](#_ENREF_89)]  Histone changes can weaken self-tolerance[[71](#_ENREF_71),[93](#_ENREF_93)]  May explain population risk differences[[25](#_ENREF_25),[26](#_ENREF_26)]  Contributes to risk burden of AIH[[23](#_ENREF_23),[25](#_ENREF_25)]  Epigenetics in AIH under-evaluated[[25](#_ENREF_25)] |
| Escaped autoreactive lymphocytes | Self-reactive thymocytes normally eliminated (negative selection)[[27-29](#_ENREF_27)]  Thymocytes recognizing foreign antigens normally retained (positive selection)[[27-29](#_ENREF_27)]  Escaped self-reactive CD4+ T cells become self-tolerant, autoreactive, or Tregs depending on PD-1 and FoxP3 expression[[112-114](#_ENREF_112)] | Escaped self-reactive CD4+ T cells may promote autoimmunity[[112-114](#_ENREF_112)]  PD-1 expression on thymocytes and lymphocytes may be impaired[[109](#_ENREF_109),[112](#_ENREF_112),[116](#_ENREF_116)]  PD-1 expression in AIH unassessed[[22](#_ENREF_22)]  Regulatory role of sPD-1 unknown in AIH[[22](#_ENREF_22)] |

Superscripted numbers are references. AIH: Autoimmune hepatitis; anti-LKM1: Antibodies to liver kidney microsome type 1*; CTLA4*:Cytotoxic T lymphocyte antigen 4 gene;DNA: Deoxyribonucleic acid; *Fas*:Tumor necrosis factor receptor superfamily member 6 gene; FoxP3: Forkhead box P3; GWAS: Genome-wide association studies; HLA: Human leukocyte antigen; PBC: Primary biliary cholangitis; PD-1: Programmed cell death antigen-1; *SH2B3*:Src homology 2-B adaptor protein 3 gene; miRNAs: Micro-ribonucleic acids; *TNF-α*: Tumor necrosis factor-alpha gene; sPD-1: Soluble programmed cell death antigen-1; Tregs: Regulatory T cells.

**Table 2 Possible triggering events for autoimmune hepatitis**

|  |  |  |
| --- | --- | --- |
| **Factors** | **Features** | **Pathogenic Implications in AIH** |
| Microbial triggers | Infections with multiple viruses temporally associated with onset of AIH[[120](#_ENREF_120),[126-128](#_ENREF_126),[133](#_ENREF_133)]  Multiple viral antigens discovered in serum and liver tissue of patients with AIH[[139](#_ENREF_139),[142-144](#_ENREF_142)] | Low frequency of viral markers in AIH[[136](#_ENREF_136),[147](#_ENREF_147)]  Undiscovered viral agents possible[[151](#_ENREF_151)]  Rarity of AIH contrasts with ubiquity of viruses and supports host-related predisposing factors[[147](#_ENREF_147)]  Microbial infection as direct cause unlikely[[147](#_ENREF_147)] |
| Superantigens | Induced by viruses and bacteria[[158](#_ENREF_158),[159](#_ENREF_159)]  No MHC-restricted antigen presentation[[158](#_ENREF_158)]  Bind to class II MHC molecule on APC and Vβ region of TCR[[160](#_ENREF_160)]  Generate polyclonal T cell response[[161](#_ENREF_161)]  Can induce T cell exhaustion[[376](#_ENREF_376),[377](#_ENREF_377)] | Superantigens implicated in model of MS and patients with RA[[165-167](#_ENREF_165)]  Associated with nearly monoclonal single type Vβ T cells in RA[[166](#_ENREF_166)]  Microbial basis inferred in RA[[159](#_ENREF_159),[166](#_ENREF_166),[167](#_ENREF_167)]  Superantigens unassessed in AIH[[158](#_ENREF_158),[159](#_ENREF_159)] |
| Drug exposure | Metabolites can interact with self-proteins to promote loss of tolerance[[176](#_ENREF_176),[178](#_ENREF_178),[179](#_ENREF_179)]  Immune checkpoint inhibitors enhance reactivity against neo-antigens[[182](#_ENREF_182),[184](#_ENREF_184)]  Immune checkpoint inhibitors induce diverse autoimmune diseases[[186](#_ENREF_186),[187](#_ENREF_187)]  Drugs can cause DNA demethylation[[199-203](#_ENREF_199)] | Idiosyncratic drug-induced liver injury can resemble AIH[[168](#_ENREF_168),[169](#_ENREF_169)]  Immune-mediated hepatitis associated with blockade of immune inhibitors[[190-194](#_ENREF_190)]  Hepatitis may occur months after cessation of immune checkpoint inhibitor[[189](#_ENREF_189)]  DNA demethylating drugs induce lupus-like reactions in animal models[[202](#_ENREF_202)] |
| Environmental Pressures | Diet, drug or alcohol abuse, pollutants, sanitation, polypharmacy, and socioeconomic status are potential but unevaluated risk factors for AIH[[25](#_ENREF_25)]  Environment can affect antigen exposures, gene expression, and immune responses[[25](#_ENREF_25)] | Vitamin D deficiency in refractory AIH[[209](#_ENREF_209),[210](#_ENREF_210)]  Vitamin D response element in genes[[378](#_ENREF_378),[379](#_ENREF_379)]  Gene expressions affected by vitamin D deficiency[[35](#_ENREF_35),[85](#_ENREF_85),[207](#_ENREF_207),[208](#_ENREF_208),[211](#_ENREF_211)]  Polymorphisms of VDR associated with occurrence of AIH[[212](#_ENREF_212),[213](#_ENREF_213)]  Other environmental factors unexplored in AIH |

Superscripted numbers are references. AIH: Autoimmune hepatitis; APC: Antigen-presenting cell; DNA: Deoxyribonucleic acid; MHC: Major histocompatibility complex; MS: Multiple sclerosis; RA: Rheumatoid arthritis; TCR: T cell antigen receptor; VDR: Vitamin D receptor; Vβ region: Variable region of the β chain.

**Table 3 Factors affecting maintenance or escalation of autoimmune hepatitis**


|  |  |  |
| --- | --- | --- |
| **Factors** | **Features** | **Pathogenic implications in AIH** |
| Molecular mimicry | Structural or conformational similarity between foreign and self-antigen[[30-33](#_ENREF_30),[215](#_ENREF_215)]  Introduced by infection, environment, or xenobiotic modification of self-antigen[[215](#_ENREF_215),[222](#_ENREF_222)]  Generates cross-reacting antibodies and immune cells[[31](#_ENREF_31),[216](#_ENREF_216)]  Requires similarity not identity to self-epitope[[31](#_ENREF_31)]  Must mimic biologically active homologue[[31](#_ENREF_31)] | Mimicries between CYP 2D6 of AIH and HCV, herpes simplex, CMV[[244-246](#_ENREF_244)]  Structural mimicry with bacteria in PBC[[247-251](#_ENREF_247)]  Virus expressing human CYP 2D6 induces experimental AIH[[226](#_ENREF_226),[252](#_ENREF_252)]  More mimicries between bacterial motifs and self-antigens than AIH occurrence suggest low impact or other factors involved[[64](#_ENREF_64),[253](#_ENREF_253),[257](#_ENREF_257)] |
| Epitope Spread | Antibodies or immune cells target multiple epitopes on same or other molecules[[37](#_ENREF_37),[38](#_ENREF_38),[264](#_ENREF_264),[268](#_ENREF_268)]  Initiating immune-dominant epitope may be lost as range of immune reactivity increases[[40](#_ENREF_40),[268](#_ENREF_268)]  Enhanced by endocytic processing and variability of peptide fragments presented by class II MHC molecules[[271](#_ENREF_271),[380](#_ENREF_380),[381](#_ENREF_381)]  Somatic hypermutation diversifies B cell receptors and their reactivity to wider spectrum of antigens[[41](#_ENREF_41),[266](#_ENREF_266),[272](#_ENREF_272),[273](#_ENREF_273)] | Autoantibody-response in murine AIH model spreads from immune-dominant epitope to neighboring and remote regions[[40](#_ENREF_40)]  Patients with AIH show similar response[[40](#_ENREF_40)] |
| Neo-antigens | Antigens released from injured tissue or formed during inflammatory activity[[42](#_ENREF_42),[264](#_ENREF_264)]  Expressed only under certain conditions[[42](#_ENREF_42)]  Can be variable between individuals[[42](#_ENREF_42),[264](#_ENREF_264)] | Can increase epitope spreading[[264](#_ENREF_264),[265](#_ENREF_265)]  May re-inforce immune response[[42](#_ENREF_42)]  Unassessed in AIH |
| Bystander activation | Induced by viral infection, bacterial products, and virus-mimetics (vaccines)[[274-278](#_ENREF_274)]  Pro-inflammatory cytokines released from T cells and macrophages activate pre-primed polyclonal memory T cells[[274](#_ENREF_274)]  Memory CD8+ T cells mainly involved[[275](#_ENREF_275),[276](#_ENREF_276)]  Memory CD4+ T cells also activated[[279](#_ENREF_279),[280](#_ENREF_280)] | Can intensify collateral tissue injury[[274](#_ENREF_274),[282](#_ENREF_282)]  Activate APCs (dendritic cells)[[274](#_ENREF_274)]  Mobilize autoreactive T cells[[274](#_ENREF_274)]  Unassessed in AIH |

Superscripted numbers are references. AIH: Autoimmune hepatitis; APCs: Antigen presenting cells; CMV: Cytomegalovirus; CYP 2D6: Cytochrome P450 2D6; HCV: Hepatitis C virus; MHC: Major histocompatibility complex; PBC: Primary biliary cholangitis.


**Table 4 Pathogenic implications of T cell antigen receptor polyspecificity and intestinal dysbiosis in autoimmune hepatitis**

|  |  |  |
| --- | --- | --- |
| **Factors** | **Features** | **Pathogenic implications in AIH** |
| TCR polyspecificity | TCRs have plasticity that increase cross-reactivity and polyspecificity[[45](#_ENREF_45),[284-286](#_ENREF_284)]  Dual TCRs escape thymic negative selection[[290](#_ENREF_290)]  Dual TCRs may recognize both foreign and self-antigens[[44](#_ENREF_44),[288](#_ENREF_288)] | Increased cross-reactivity, promiscuous targeting, and less self-tolerance[[45](#_ENREF_45)]  Unassessed in autoimmune hepatitis |
| Intestinal dysbiosis | Intestinal dysbiosis associated with activation of TLRs, inflammasomes, and stimulation of immune response[[296](#_ENREF_296),[303](#_ENREF_303),[304](#_ENREF_304),[306](#_ENREF_306),[307](#_ENREF_307),[309](#_ENREF_309)]  Gut-derived activated immune cells migrate to peripheral lymph nodes[[310](#_ENREF_310),[311](#_ENREF_311)]  Transfer experiments using intestinal microbiota affect female bias for diabetes[[300](#_ENREF_300),[332](#_ENREF_332),[333](#_ENREF_333)]  Exposure to gut-derived microbial products at young age may protect against intolerance to self-antigens (“hygiene hypothesis”)[[334-337](#_ENREF_334)] | Present in diverse liver and non-liver autoimmune diseases[[249](#_ENREF_249),[302](#_ENREF_302),[303](#_ENREF_303),[318](#_ENREF_318),[323](#_ENREF_323),[325](#_ENREF_325)]  Deficient structural proteins of mucosal barrier in AIH[[325](#_ENREF_325)]  Circulating gut-derived bacterial lipopolysaccharide in AIH[[325](#_ENREF_325)]  Decreased intestinal anaerobes in AIH[[325](#_ENREF_325)]  Dysbiosis associated with flares in experimental AIH[[326](#_ENREF_326)]  May influence female gender bias in autoimmune disease[[300](#_ENREF_300),[332](#_ENREF_332),[333](#_ENREF_333)] |

AIH: Autoimmune hepatitis; TCR: T cell antigen receptor; TLRs: Toll-like receptors; Tregs: Regulatory T cells.



**Figure 1 Pathogenic mechanisms implicated in autoimmune hepatitis.** The components of each putative mechanism are shown under each panel as bulleted items. MHC: Major histocompatibility complex; TCR: T cell antigen receptor; PD-1: Programmed cell death protein-1.



**Figure 2 Pathogenic mechanisms and factors associated with susceptibility, onset, and maintenance of autoimmune hepatitis and possible therapeutic interventions.** Pathogenic mechanisms and factors are shown as bulleted items, and possible therapeutic interventions for each aspect of the disease are indicated alongside the arrows. PD-1: Programmed cell death protein-1.